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ABSTRACT 
BACKGROUND 
Obstetric blood loss is the major cause of maternal mortality and 
cesarean section accounts for 25 -30 % of all deliveries. Delivery by 
cesarean section is associated with primary and secondary hemorrhage. 
Tranexemic acid is a synthetic derivative of amino acid lysine that exerts 
its anti fibrinolytic effects by its reversible blockade of lysine binding sites 
on plasminogen molecules. 
Tranexemic acid is highly effective in reducing blood loss and hence 
the need for blood transfusion is also reduced in almost all kinds of 
surgery. 
OBJECTIVES 
Main objective is to study the effectiveness of prophylactic 
parenteral  tranexemic acid in reducing blood loss during and after elective 
lower segment cesarean section. 
METHODS: 
  A prospective randomized case control study conducted from 
August 2014 to August 2015  on 150 women who underwent lower 
segment cesarean section .75 of the cases were given tranexemic acid  
 
 
before 20 minutes of skin incision. Other 75 subjects were not given 
tranexemic acid. The amount of blood loss from the end of placental 
delivery to two hours post partum was measured along with the vital 
parameters and adverse effects were compared among both the groups. 
RESULTS 
Tranexemic acid significantly reduces the amount of blood loss from 
the end of placental delivery to two hours post partum. In the present study 
it was observed that blood loss from the end of placental delivery to the 
end of surgery is 300 ml in study group and 380 ml in control group. In 
similar manner the amount of blood loss from the end of surgery to two 
hours post partum is 40 ml in study group and 70 ml in the control group 
with p value of <0.001   which is satistically significant. No complications 
or side effects are reported among both the groups. 
CONCLUSION 
Tranexemic acid significantly reduces the amount of blood loss  
during and after cesarean section and it was not associated with any 
significant side effects. Tranexemic acid can be used effectively in all 
women undergoing lower segment cesarean section. 
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INTRODUCTION 
Obstetric blood loss is a major cause of maternal mortality and is 
always under estimated and hence blood is inadequately replaced. 
Caesarean section rate has been increasing nowadays accounting for 25 to 
30 % of all deliveries
1
 Caesarean section is specially associated with 
varying amount of blood loss.  Though active management of third stage 
of labour is practiced well and it can prevent 60 %of post partum 
hemorrhage but still PPH has a devastating impact on the society with 
increased maternal mortality and morbidity. 
The importance of tranexemic acid is that as it reduces blood loss as 
well as reduce the need of blood transfusion .Blood is a precious product 
in which patients are associated with risk of transfusion related adverse 
effects such as febrile non hemolytic transfusion reactions and blood borne 
infections.
2 
Tranexemic acid is a synthetic derivative of amino acid lysine that 
exerts its anti fibrinolytic effect through reversible blockade of lysine 
binding sites on plasminogen molecules.
3,4
 Intravenous administration of 
tranexemic acid before skin incision routinely decreases the amount of 
blood loss during any surgery and also reduces the incidence of blood 
transfusion during surgery. 
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Tranexemic acid potentiates the blood clotting system as it is an anti 
fibrinolytic agent and is used to treat and prevent bleeding. During 
placental delivery rapid degradation of fibrinogen and fibrin occurs, as 
well as an increase in the activation of plasminogen activity and fibrin 
degradation products due to activation of the fibrinolytic system .This 
activation lasts for 6 to 10 hours post partum which may cause more 
hemorrhage .The anti fibrinolytic effect of tranexemic acid in the third 
stage of  labour  could make it safe and effective  alternative or can be used 
as an adjunct to other regimen in the third stage of labour for prevention of 
post partum hemorrhage.
5 
In this present study the effectiveness of prophylactic tranexemic 
acid in reducing the blood loss from the end of placental delivery to two 
hours post partum in the third stage of labour during caesarean section has 
been investigated. 
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OBJECTIVE 
The main objective of the study is to evaluate the effectiveness of 
tranexemic acid which when used prophylactically before skin incision is 
highly effective in reducing blood loss during and after elective lower 
segment ceasarean section. 
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REVIEW OF LITERATURE 
Blood has two remarkable properties. It   remains   in  the  fluid  
state in  the  blood vessels  throughout  life, but  rapidly  becomes jelly  
like  when shed. Both these properties are essential for the preservation of 
life.  The latter property of blood  that  is  losing  its   fluidity  and  setting  
into   a semisolid jelly  when  shed   or  when   collected  in  a  test   tube  
is  clotting or coagulation  of  blood. 
When the process of coagulation is studied under an electron 
microscope, it   is seen that minute granules appear at first, often near a 
clump of disintegrating   platelets. These  granules join together  to form a 
tough resilient meshwork of fibrils  in  which the cellular elements  of  
blood get  entangled  as  in  a net. These fibrils are composed of fibrin. 
Coagulation is the  property of plasma  alone ;  the red  and white 
corpuscles  do  not take part   in   it.  They   only   become   caught  up  in  
the  meshes   of  the clot  giving    the  characteristic    appearance  of  a  
clot.  It   is   due  to  the incorporation  of  the  red  cells  that  the  clot  
appears  red. When   the clot subsequently contracts, a clear straw - colored 
fluid, called   serum,  is left  behind. This will not clot any more. 
The  essential  reaction  in  the conversion of  the  soluble hydrosol 
form  of  protein  (fibrinogen )  into  an  insoluble  hydrogen  form  (fibrin) 
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by means of an enzyme  thrombin. While fibrinogen exists in the 
circulating  blood  as such, thrombin is formed from an inactive  
circulating precursor called prothrombin, from the blood which is shed. 
The activation   of prothrombin is brought about by the formation of 
prothrombin activators  through a  number of  reactions of coagulation 
factors  in the  plasma, and from damaged tissue and from platelets. 
          Numerous  theories have been  proposed to account  for  the  clotting 
of blood  and a complicated  and  often   confused   array  of  terminology 
had  sprung  up  in  this  field. To clarify  the  situation  and  to  bring  
about a certain order, an international  committee, which  included the 
world‟s leading authorities on blood  clotting  was  appointed.  
       They recommended that roman numerals should be used to describe  
the factors and gave a list of accepted factors as follows: 
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FACTOR I  -- FIBRINOGEN 
FACTOR II -- PROTHROMBIN 
FACTOR III -- TISSUE THROMBOPLASTIN 
FACTOR IV – CALCIUM 
FACTOR V – LABILE FACTOR, ACCELERATOR  
    GLOBULIN 
FACTOR VI -- UNASSIGNED FACTOR 
FACTOR VII -- STABLE FACTOR /SERUM   
    PROTHROMBIN CONVERSION   
    ACCELERATOR 
FACTOR VIII – ANTI HAEMOPHILIC GLOBULIN 
FACTOR IX -- CHRISTMAS FACTOR 
FACTOR X -- STUART PROWER FACTOR 
FACTOR XI – PLASMA THROMBOPLASTIN   
    ANTECEDENT 
FACTOR XII – HAGEMAN FACTOR/ GLASSS FACTOR 
FACTOR XIII – FIBRIN STABILIZING FACTOR. 
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However, they agreed  that  the  first four factors could be called by 
their names, as  these  names are well established.  The activated form of  
the factor is indicated  by  the  subscript  „a‟  after   the  number. 
BLOOD CLOTTING FACTORS 
FIBRINOGEN 
Fibrinogen is a plasma globulin formed in the liver. It is a dimer 
having two sets (A&B) of three linked polypeptide chains. Clot  is formed  
by the conversion  of  fibrinogen   into  fibrin  by  the  action  of thrombin. 
Only fluids containing  fibrinogen can clot. Hence plasma can clot but not 
serum. 
PROTHROMBIN 
Prothrombin is a plasma globulin formed in the liver   and requires 
vitamin K. It is a monomer and is a proenzyme and a precursor of 
thrombin.  Its plasma  concentration   is  about  15  mg /100   ml  and  its  
half-life  is  about  3-4  days.  It is absent in the serum. 
THROMBIN 
Thrombin is not  normally present  in  the  plasma. It  is  formed   
from prothrombin by  the action of prothrombin  activators  in  the   
presence   of Ca
 ++
  ions  .It  is  a  protein  with   a  molecular  weight  of  
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about 34000.  It enzymatically converts fibrinogen to fibrin. It can also 
activate factor V & VII, and promotes platelet aggregation and activation. 
TISSUE THROMBOPLASTIN 
Tissue   thromboplastin   is released by injured  tissues   and   is  
composed of tissue factor (a proteolytic enzyme ) and tissue phospholipid. 
It  activates   factor  VII. Thromboplastin  is  liberated   from  all  tissues,  
but the most  potent  thromboplastin are found  in  extracts  of  brain ,  lung  
and placenta. 
CALCIUM 
Ionic calcium is  essential  for  clotting  of  blood  .Decalcified  
blood   does  not  clot .  Calcium ions are necessary for the activation of 
factors IX and X.  Formation  of  prothrombin  activators  ,  and  for  
activation  of  factor  XIII. 
FACTOR V (Labile factor, Accelerator globulin) 
It  is  a  heat  labile  high  molecular  weight  protein  formed  in  the   
liver. It is  activated  by   factor  X  and  thrombin  ,  and   is  a  co  factor  
in  the formation   of   prothrombin  activator  . It is used up during   
clotting   and is absent in the serum.  Its   plasma half-life is  about 36 
hours. 
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FACTOR  VII (Stable  factor ,  or  Serum  Prothrombin  Conversion  
Accelerator  SPCA ) 
It  is  a  protein  formed  in  the  liver  and  requires  Vitamin K  for 
synthesis.  It is  activated   by  tissue  thromboplastin  ,   and  is  a  
proenzyme for  the  activation   of  factor  X.  Its plasma half-life is 4 - 6 
hours. 
FACTOR VIII (Antihaemophilic globulin AHG, or AH factor A) 
It is a high molecular weight globulin formed in the liver.  It  is 
transported  in  the  blood   combined  with  another  protein  von  
willebrand Factor (vWF)  which  is  formed   in  the   vascular  
endothelium  (and  also  in the  megakaryocytes). Factor  VIII  is  activated   
on   separation   from  vWF by  thrombin  and  is  a  cofactor  in  the  
intrinsic  pathway. It is used up during clotting and is absent in the serum.  
Its plasma life is about 12hours.Its deficiency   causes   Hemophilia A 
(vWF can also favor platelet adhesion) 
FACTOR IX (Christmas factor, AH factor Plasma thromboplastin 
component PTC) 
It  is  a  protein  formed  in   the  liver  and  requires   Vitamin  K  .It  
is activated  by  factor  XI a and   is  a  pro  enzyme  in  the  intrinsic  
pathway. Its Plasma half-life is about 24 hours. It is not   used   up in 
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clotting and is present in serum.  It  is called  Christmas  factor  , because  
this  factor  was  first   found  to  be  deficient  in  a  patient  named   
Christmas. Deficiency of  this   factor  causes   Christmas   disease   or  
Hemophilia  B. 
FACTOR X (Stuart prower factor) 
It is a two chain protein formed in the liver and requires Vitamin.K. 
It  is  a  pro  enzyme  for  the  formation   of  prothrombin  activators  
in  both intrinsic  and  extrinsic  coagulation   pathways.  It  is  activated    
by  active factors  VIII  and  IX  in  the  intrinsic  pathway    and  by   
factor   VII a  in the  extrinsic  pathway . Its plasma half-life is about 24 to 
40 hours. It is present in the serum. 
FACTOR XI (Plasma thromboplastin antecedent PTA or AH factorC) 
It  is   a  pro  enzyme  in   the    intrinsic   pathway,  which  activates   
factor IX and  is  activated   by  factor  XII  and  by  HMW  kininogen. 
This protein is formed in the liver.  Its   plasma  half-life  is  2 to 3 days,  
and is present  in  the  serum. 
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FACTOR XII (Hageman factor, Glass factor) 
It   is a protein   formed   in the liver. Its  plasma  half-life  is  about  
2  -3  days   and   it  is  present   in  the  serum. It  is  activated   by   high   
molecular  weight  kininogen  and   prekallikrein ,  and  by  contact  with   
sub endothelial  collagen   in  the  injured  vessel. (Contact  with   
negatively  charged  glass  surface   also  activates  factor  12 ).Activated  
XII  converts  pre  kallikrein  to  kallikrein,  which    further   activates   
factor  XII . Activated  factor  XII is  an  intact   pro  enzyme  which  
activates   factor  XI along   with  HMWK.Activation  of   factor  XII  is  
the   first  reaction   that initiates   the  process  of  coagulation,   as   
observed   in  test  tube.  However   factor  XII  deficiency  does  not  result  
in  a  clinical  bleeding  disorder, whereas  factor XI  deficiency  does. 
Hence Factor  XI activation  must  be  considered   to   be an  important  
initial  reaction  and  there  is  apparently   some  mechanism   in addition   
to  factor XII, involved  in  activation  of  factor  XI. 
FACTOR XIII (Fibrin stabilizing factor Laki- Lorand factor) 
It is a protein  with  2 alpha and 2 beta  chains  with  a  plasma  half-
life 5 -7days.  It is formed in the liver   and probably megakaryocytes.  It  
is  activated  by  thrombin  in  the  presence  of  Ca  2++  by    forming 
cross  linkage  between  the  fibrin  monomers  and  polymers. 
12 
 
PREKALLIKREIN (Pre-K, Fletcher factor) 
It  is  a  globulin   and  is  a  part  of  the  kinin  system.  It   activates  
factor XII which  in  turn  activates   prekallikrein   to  kallikrein  .This  pro 
enzyme is  also  involved  in  the  activation  of  factor  XI 
HIGH MOLECULAR WEIGHT KININOGEN: (Fitzgerald factor) 
It is an alpha globulin and is a   cofactor in the   activation of factor 
XI and XII. 
PLATELET PHOSPHOLIPID 
Injury   to   a   blood  vessel  causes  platelet  aggregation  as  well  
as release   from  damaged  platelets  , platelet  phospholipids  which  is  a   
cofactor in  the   conversion   of  prothrombin  to  thrombin. 
THE MECHANISM OF COAGULATION 
The formation   of a clot involves three basic steps.  There are 
1. Formation of prothrombin activators through two pathways 
a) Intrinsic pathway 
b) Extrinsic pathway 
2. Formation of thrombin 
3. Formation of fibrin 
13 
 
1. FORMATIONOF PROTHROMBIN   ACTIVATORS 
a) INTRINSIC PATHWAY 
It  is  a  series  of  cascading  reactions  that  set  up  by  trauma  to  
blood,  with  contact  of  blood  with  sub endothelial   collagen  ,  and  the  
release   of  phospholipid  from  platelets. 
The  first  reaction  is  the  activation   of  factor  XII    to   XII a 
with the  help  of  pro  enzyme  Pre –K  and  Cofactor  HMWK. XIIa itself 
activates Pre -K which further increases XIIa formation. 
1. XIIa   with    HMWK and Pre –K   convert   XI to XIa.  
2. Now XI a in the presence of Ca++ activates IX to IXa. 
3.  Factor VIII is activated to VIII a by thrombin. 
4. IXa   along  with   cofactors   VIIIa  and  phospholipid  ,in  the 
presence  of  Ca
++
  converts  X  to  Xa. 
5. Factor   V   is activated to Va by thrombin. Xa  with   co factors Va  
and  phospholipids  in  the  presence   of  Ca
++
  is  the prothrombin 
activators  which  converts  prothrombin  to thrombin. 
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b) EXTRINSIC PATHWAY 
1. The   process  is  initiated  by  trauma  to  tissue   , which  causes the  
release  of tissue  factor  and  tissue  phospholipids (tissue 
thromboplastin) from   injured tissues. 
2. Tissue  thromboplastin  activates  factor  VII  to VIIa which  along  
with tissue phospholipid  in  the  presence  of  Ca
++
   activates  factor  
X to  X a. 
3. Activates  X (Xa)  along  with  co  factors Va  and  phospholipids  
and  Ca
++
  is  the  prothrombin  activator. 
2. FORMATION OF THROMBIN 
The  prothrombin  activator  with  cofactors  Va  and  phospholipids  
in  the  presence  of  Ca
++
  converts  prothrombin  to thrombin. As soon  as   
prothrombin  activator  is  formed   and small  amounts  of thrombin   are  
formed ,  the   process   of  clot  formation  is accelerated  as  thrombin  
activates  many  of  the clotting  factors. The  time  taken  for  clot  
formation  is  due  to  the  time  taken  for formation  of  prothrombin  
activator, especially  via  the  intrinsic pathway  which  may  take  a  few  
minutes. The extrinsic  pathway  is  more  rapid  and  may  occur  within  a  
minute. 
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3. FORMATION OF FIBRIN (CLOT) 
1. Thrombin converts fibrinogen to fibrin.  It  removes  small peptides  
from  the  alpha  and  beta  chains  of  fibrinogen  to  form fibrin  
monomers  which  soon  polymerizes  and  form  fibrin polymer. 
2. Thrombin acts on the fibrin stabilizing factor XIII and activates it to 
XIIIa. This  is  an  enzyme (transglutaminase ),which  in  the  
presence  of  Ca
++
  sets  up  cross  linkages between  the  fibrin  
fibers  to  form  cross  linked  fibrin  or  stable fibrin. 
3. The  fibrin  fibers  form  a  network  of  delicate  thread  like fibrils  
in  which  RBC,WBC,Platelets  and  plasma  are entrapped. 
4. The  clot  becomes  attached  to  the  opening  in  the  injured vessel,  
as  the  fibrin  fibers  become  adherent  to  the  wall  of  the  vessel  
in  the  injured  region. This helps to prevent further bleeding. 
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FIGURES.1 BLOOD COAGULATION PATHWAY  
LYSIS OF CLOT (Degradation of Fibrin, Fibrinolysis) 
In  a day  or  two  after  clot  formation  and  cessation  of  bleeding, 
the  process  of  degradation  of  clot  begins. The  lysis  of  the  clot  is  
brought  about  by  the  action  of  a  proteolytic  enzyme  called   plasmin . 
Plasmin  is  not  normally  present  in  the plasma,but is  formed  from  its  
precursor  plasminogen  which  is a globulin   formed  in   the  liver  and  
present   in  the  plasma .Activation  of plasminogen  is  brought  about  by  
plasminogen activators  formed in  the  vascular  endothelial  cells.  
 
17 
 
The sequence of events is as follows: 
1. Release of plasminogen activators. The  formation  and deposition  of  
fibrin  in  the   vessel  wall ( and  probably  the thrombin  formed  as  
well)  stimulates  the  production  of  two plasminogen  activators 
a) tissue  type  (t- PA) 
b) urokinase  type   (u – PA) from  the  endothelial  cells 
2. The  t-PA  and  u-PA,  which   are   protease   enzyme  act   on 
plasminogen  trapped   in  the  clot  and  convert  it   into  plasmin 
3. The plasmin acts   on the fibrin and   fibrinogen and breaks them   
down   to   smaller   soluble   products   called   fibrin degradation   
products.  Plasmin    also  digests  the  products  and thus  dissolves  
and  removes  the  clot  slowly  in  a  few   days. The  process  of  
fibrinolysis  is  regulated  by  controlling   the  activity  of  
plasminogen activators. This  is  done  by  plasminogen activator  
inhibitors, which  are  also  released  by  vascular endothelial  cells. 
The  plasmin  that  enters   the   plasma ,  or  small  amounts   formed    
in  the  plasma   is  promptly  inactivated  by  the   alpha -2  
antiplasmin, which  is  formed  in  the  liver   and  is  present  in  small  
concentration   in  the  plasma. 
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FIGURES.2 MECHANISM OF FIBRINOLYSIS 
FACTORS PREVENTING INTRAVASCULAR COAGULATION 
Apart   from  smoothness  of  the  vascular  endothelium which  
prevents  contact  with  collagen ,  there  are substances   such  as  protease   
inhibitors   and  other   which  prevent   clot   formation  in  the  uninjured  
vascular  system .  
 
19 
 
Some of these are: 
1. Anti-thrombin 3 which is a protease inhibitor. It  is  a  globulin  .It 
links  to  heparin  present  in  the  blood  and  the complex  formed   
becomes   a  potent   anticoagulant   ,and  acts   by  inactivating  the   
active  forms  of   factors IX, X, XI, XII .It  also  binds  with   the  
thrombin  that  has   not  been  absorbed   to  fibrin  fibers ,  and  this   
inhibits    the effects   of  thrombin  on  fibrinogen. 
2. Thrombomodulin   is  a  protein  formed   by  the   capillary  
endothelial  cells ,  and   is  present  bound   to  endothelial 
membrane. It forms a complex with thrombin.  The thrombomodulin   
- thrombin  complex   activates   protein C,in  the  presence  of  
cofactor   protein S   to  form  activated  protein  C. The  APC  
inactivates   factors   VIII a   and  Va. Protein  C  and  Protein  S  are   
formed   in  the  liver,  in   the presence   of  Vitamin  K  and  are   
present   in  the  plasma. The   binding   of thrombomodulin to 
thrombin complex   also favors   fibrinolysis   by   inhibiting   the 
inhibitors of plasminogen   activators   and   increasing   plasmin 
formation. 
3. alpha  2  macroglobulin  ,which  is  a protease  inhibitor  which  is  
present  on  the  endothelial  surface   also  prevents  activation   of  
several   coagulation   factors   of  the  intrinsic  pathway  and  
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appears   to  act  in  a  manner   similar   to anti thrombin   3-  
heparin  complex,  except  that   it  does   not  need    heparin   for  
activation. It also   combines   with thrombin and   limits   its   action   
on fibrinogen. 
4. Extrinsic  pathway  Inhibitor: A new  factor  which  causes 
inhibition  of  the     extrinsic  pathway   has  been   recently 
identified. This  is  referred  to  as  extrinsic  pathway   inhibitor or  
lipoprotein  associated   coagulation  inhibitor. The Extrinsic 
pathway   inhibitor   along   with Xa inhibits   the   enzymatic 
activity   of   factor VIIa / Tissue factor complex. 
HAEMOSTASIS 
Homeostasis   is   arrest of bleeding.  The    process   of coagulation   
of blood takes 5 minutes to occur and is the secondary mechanism. . The 
immediate (primary) mechanism which occurs within seconds is 
a) vasoconstriction  at  site   of  injury 
b) Platelet plugs formation   which   seals   the   opening   in the   
injured   vessels. 
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FIGURES.3 MECHANISM OF HEMOSTASIS 
VASOCONSTRICTION 
Immediately after injury blood vessel constricts.  This  is largely  
due  to  the   local  response  of  vascular  smooth muscle  to  trauma  
causing  the  muscles  to  powerfully  contract.   The  contraction   may  
last   for  a  few  minutes   and is  probably  aided  by  release   of  some   
vasoconstrictor  substances  from  the  platelets.  Even in large blood   
vessels   like   the radical    artery   may be fully constricted for a while. 
This   immediate response   helps   prevent excessive bleeding   from   the   
site   of injury. 
FORMATION    OF   PLATELET PLUG 
This   process   begins   within    a few    seconds   after injury and 
involves three mechanisms 
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a) Platelet   Adhesion 
b) Platelet   Activation 
c) Platelet  Aggregation 
 
FIGURE.4 PRIMARY HEMOSTASIS 
a) PLATELET   ADHESION 
When a blood   vessel   is injured,   its   sub endothelial   collagen    
is exposed,   and platelets   adhere   to   the    collagen.  This process is   
assisted   by   the   von Willebrand factor (vWF)    which   is   present in 
the   platelets    as   well   as  in   endothelial   cells. 
b) PLATELET   ACTIVATION 
This   process  is  initiated   by  the  adherence   of   platelets    to 
collagen   and  is  facilitated   by   thrombin,   thromboxane   and   platelet  
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activating   factor    which   is  a   cytokine    secreted    by  platelets    as 
well  as   neutrophils    and    monocyte  .The   activated   platelets  swell 
change  shape   throw     out    pseudopodia   and  release    the   contents   
in their   granules.  
c) PLATELETS    AGGREGATION 
The    secretion   causes   the platelets   to get sticky and adhere to 
one another.   The   activation   of   the platelets    draws   more   platelets   
towards them and activates them    and these    platelets   attach to the 
collagen.  As  aggregation   occurs  the  mass  of  platelets  grow  in  size  
and form  a  haemostatic  plug  which   may   be  quite   effective   in  
sealing  off small  opening   in  blood vessels. Integrins   which   bind to  
receptors,  are  one   type    of   cell  binding  proteins   called   Cell   
Adhesion  Molecule   .Integrins are    considered  to  play  a main  role  in  
platelet   adhesion   and  aggregation. 
During   day   to  day   activities   one   frequently   sustains   minor  
trauma which  is  liable   to  cause   bleeding   from  capillaries. It  is  the   
prompt formation   of  platelets   plug   that  seals   off   small  openings   
in   capillaries  and  small  venules   that  prevent   bleeding.  In platelet  
deficiency   small haemorrhages  under   the    skin   and  other  parts   
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occur.  Platelets   also have   a   role  in  coagulation  - eg  : formation  of   
platelet    phospholipids. 
The   events   that   follows   an injury   to  a  blood   vessel   are    
1. Vasoconstriction 
2. Platelet  plug  formation 
3. Blood  coagulation 
4. Clot  retraction 
5. Fibrinolysis 
The  processes   are  integrated   with  one   another.  The   first    
two   forms  the   primary  haemostasis   and  the   third   secondary   
haemostasis. 
COAGULATION  IN  PREGNANCY 
Placental   separation that  occurs  during  the   third  stage   of   
labour   is the  major   haemostatic   challenge   in  pregnancy.  Myometrial 
contractions  brings   about significant    constriction  of  blood  vessels in  
the   placental  bed but  adequate   fibrin   formation   is  also  required. 
Many  physiological  adaptation  takes  place   during  pregnancy  
and  the haemostatic   challenge   is  met  in   almost   all   pregnant   
women   as  pregnancy   is   always   represented    as  a   hypercoagulable   
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state. The  concentration   of   many   clotting   factors   increases   during 
pregnancy   which   includes    factor   II ,VII, VIII, IX,  XII.  The 
concentration   of   clotting  factors   that  tend  to  decrease   during  
pregnancy  is  that  of   factor   XI  and   XIII  which   occurs   mainly  
during  the   third   trimester    of pregnancy. 
TRANEXEMIC  ACID 
 
FIGURE 5 CHEMICAL STRUCTURE OF TRANEXEMIC ACID 
Tranexemic  acid  is  a  synthetic   lysine   aminoacid   derivative, 
which literally   diminishes   the  dissolution  of  hemostasic  fibrin   by  
plasmin  by   exerting   its   anti  fibrinolytic   effects   by   reversible    
blockade   of lysine   binding   site    of   plasminogen   molecules.
7,8 
Thus  the  lysine  receptors   binding   sites    of   plasmin   for   
fibrin    are well  occupied    by   tranexemic  acid   thus  preventing   
binding    by  fibrin molecule   and   hence   preserving  and  stabilizing   
fibrin   matrix. 
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The  anti  fibrinolytic   effect   of   tranexemic  acid   is  mainly   
mediated  by  reversible   interaction   that   occurs   at   multiple   binding   
sites   of plasminogen. Actually   human  plasminogen   contains   4  to   5   
lysine binding   sites   which   has   low    affinity    towards   tranexemic  
acid   and only  one   high   affinity   sites. This  high   affinity   site   is  
mainly involved  in   its   binding   with   fibrin   saturation  of   this   high    
affinity  binding   site  with   that  of   tranexemic   acid   leads  to   
displacement   of plasminogen  from   its   surface    of   fibrin   .  Inspite of  
the   fact   that  plasmin   may   be formed    just   by   conformational   
changes   in plasminogen,   the   process   of   binding    to   fibrin   and   
dissolution   of   the   fibrin    is  totally   inhibited   by   tranexemic acid.
9 
 
FIGURE 6 TRANEXEMIC ACID INJECTION 
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PHARMACODYNAMICS 
Tranexemic   acid  reduces  20 -60  %  the   rate   of   lysis  of  fibrin  
which   is  catalyzed    by  tissue   plasminogen  activators
10
. In  all   
healthy   individuals  ,tranexemic   acid  when   in  concentration of  10  
mg /ml  in   the  blood  has   no   effect   on  the   platelet   count   as well  
as   various   coagulation   factors and  hence   no  change   or  effects   on 
the  coagulation   time.                     
GNK 30
Lysine Binding 
Site
FIBRIN
PlasminogentPA
Fibrin
Maxna blocks 
lysing-binding 
site and 
prevents 
bleeding
GNK 32
 
FIGURE 7 MECHANISM OF ACTION OF TRANEXEMIC ACID 
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PHARMACOKINETICS 
ABSORPTION 
After    a single   oral   administration   the peak concentration   in 
plasma occurs   approximately   by 3 hours. Tranexemic acid can be 
administered without regards to meals.
11, 12. 
DISTRIBUTION 
 Tranexemic  acid  is  3 %   plasma  bound  with  no  apparent    
binding with  albumin
10 
 Tranexemic  acid   crosses   placenta ,  the  concentration   in  cord  
blood    is   30  mg/L   after   intravenous  injection   of  10  mg/kg  
of tranexemic  acid in  pregnant  women.
13
 
 Tranexemic  acid   gets   one  tenth  concentration  in  cerebro spinal  
fluid  as  that   in  the  plasma.
14
 
 Tranexemic  acid   also  passes   into   aqueous   humor   of  eye  and  
gets   one  tenth   concentration   as  that   in  plasma.
15
 
METABOLISM 
Only  a  small  fraction   of  the  drug   is   metabolized
16 
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EXCRETION 
Tranexemic  acid   gets   eliminated   via   urinary   excretion   that 
too   primarily   by   glomerular   filtration   with   more  than   95 %of   
drug   excreted   unchanged.  90  %   of  drug   get eliminated   within24   
hours   of   intravenous   administration. After  intravenous dosage  most  
of  drug   gets   eliminated during  the   first   10  hours   followed    by   
other   fractions   . Thus elimination half  life   is  estimated to  be  2  
hours.  
17 , 18. 
USES  OF  TRANEXEMIC  ACID 
CARDIAC SURGERY 
In  patients   undergoing   cardiac   surgery   mainly  with   cardio 
pulmonary  bypass  peri operative    treatment   of  tranexemic acid  as  a  
intravenous   loading   dose   results    in   significant  reduction   in   blood   
loss  that  may    occur   post  operatively.
19, 20 
A meta-analysis   of   nearly   60   randomized clinical  trials   in  
cardiopulmonary    bypass   showed    that    tranexemic   acid  is   solely   
associated    with   a  significant   reduction    in proportion   of   cardiac   
patients    requiring    blood    transfusion  peri  operatively.
30 ,31, 32. 
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ACUTE   UPPER   GASTRO  INTESTINAL   BLEEDING  
Highly great statistical   significant  data  results   of reduction    of  
blood   transfusion requirement with that of tranexemic  acid  therapy  with   
upper   gastro  intestinal  bleeding   patients    has  been    obtained   in   
many   published   trial.
33 ,36, 37. 
Meta  analysis reveals   that   tranexemic   acid    reduces the risk of   
rebleeding   by  30  %  and  30 %  to 40%   reduction   for  need of  surgery     
and   last    but   not  the  least   reduces   mortality   by  40  %
34 ,35. 
ORAL  SURGERY 
When   tranexemic  acid    is   used   as   a   mouthwash   after   oral  
surgery 
38
 in   patients    receiving   oral   anticoagulants   therapy   ranges   
between   0  to   6.7 % 
42, 43, 44.
   only   compared   to   the  placebo    where    
the  rate   ranges   from   13.3  to   40  %
38 , 39, 40 ,41
 
OTHER  SURGERY 
The list   of   use   of  tranexemic   acid    extends    way   ahead  , it  
is    significantly   useful   in   the   following   surgeries.   
 Total   knee  replacement57, 58. 
 Orthotopic   liver  transplantation59, 60 ,61 
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GYNAECOLOGIST 
Tranexemic    acid   plays a vital role in all gynaecologist   practice.  
It  is  a effective  method   to  control  bleeding  which   may   be  either    
menorrhagia,  peri  operative  loss.
23, 24, 25 
MENORRHAGIA 
The   main   outpatient   population   comes   commonly  with 
complaints   of  excessive   bleeding    per  vagina. During   normal   
periods   the   amount   of   blood   loss   is approximately    30  -50  ml.  if   
the   blood   loss   is   more than   80  ml  ,it  is    defined  as  menorrhagia    
Many  trials has    been   conducted   which   has  resulted   in   nearly   50 
%  reduction   of  blood  loss   during  menstruation.
21 ,22. 
BLEEDING   ASSOCIATED   WITH   PREGNANCY 
During pregnancy   bleeding    may   occur    due   to     
1. Postpartum   hemorrhage 
2. Abruptio placenta   
3. Placenta  previa 
Various   studies   has   demonstrated    that   usage  of  tranexemic   
acid   has  been   associated    with    three  to   four fold   increase   in   
perinatal   morbidity. In   case   of   abruption  placenta   studies   have 
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shown   that   perinatal    mortality   is  reduced   by  8  %. It   also   
reduces   the   amount    of   blood  loss  in  case   of   central   placenta  
praevia who   presents  as   obstetric   emergency   with   that   of   heavy  
bleeding.
26,27 
Various   randomized   multicentric   trials   discuss   significant   
reduction  in  bleeding   after   placental  delivery   to   two   hours 
postpartum   with   no  associated  side   effects.
28 ,29. 
HEREDITARY   ANGIONEUROTIC  EDEMA
64, 65. 
Hereditary   angioneurotic   edema   is  mainly   characterized  by  
recurrent   non  pitting   sub  epithelial  edema   which may   involve    any  
part   of   body. In  double   blind   studies   conducted results  in reduction   
of   severity  of   attacks   of   edema    when  tranexemic acid   is  giving   
at  a  dose  of  1.5  g/day   for   seven   days  after  attack.
66 ,67, 68 
SUBARACHNOID   HEMORRHAGE 
Rupture   of   any   of  the   intracranial   aneurysm   results in  
bleeding    into    the   subarachnoid   space. In  a   study    where   the   
patients   who   received  anti  fibrinolytic   therapy   as    compared     to   
those   who did   not    receive    the  treatment,  resulted   in  significant 
reduction   in  the   rate   of  re-bleeding.
69, 70, 71, 72. 
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USE IN   TRAUMATIC   HEMORRHAGE 
In   our   body, almost hemostatic   system  maintains  the integrity   
of   circulating    system   after   every   vascular injury   which    may   be    
traumatic  or   surgical    in  its   origin.
45, 46, 47,48.
 Major   trauma   or  
surgery   brings    about    a  trigger  in  the   hemostatic   system    of  the   
body   or   it  may   be even   from  the  massive   loss   of   blood   from   
the  body
53, 54, 55.
.   All these   provides   the   coagulation   system  of our   
body  which  is  a    major   challenge. In   this   place  anti  fibrinolytic   
agent   plays  a  major   role in   the   reduction   of   blood   loss   without   
increasing  any  risks   of   post  operative   complications    as  well   as  
no   increase    in   the   risk  of   venous    thromboembolism. Many   
studies   have  been   conducted    which    showed  results   has   
significantly   reduced   in  the   need   for transfusion    by   one third   as   
well   as   reduced    the volume    of   transfusion   by  one   unit   and  also    
has  halved   the   need    for    further   surgery   in order   to control   
bleeding
49
. These   differences   were   all   satistically    significant   as  
that anti  fibrinolytic   agent   reduces   blood  loss   need for  transfusion   
and   mortality. The  blood  is  a    scarce   and  expensive    resourse    and   
major   concern    regarding   risk  of   transfusion transmitted   infection, 
thus   a  simple  and   widely   accepted     practice    of   using   anti  
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fibrinolytic    agents  that    reduces   blood   loss   following    may   be 
trauma or   surgery     and   hence    prevents   thousands    and thousands    
of   death   each   year   and   it  may   also reduce  exposure     to   all   the   
risk    of    blood transfusion.
50 
The   large   trial   namely CRASH  2 . THE   CLINICAL  
RANDOMIZATION  OF   AN   ANTI  FIBRINOLYTIC    IN  
SIGNIFICANT   HEMORRHAGE
56 
 where   the   comparison  between   
anti  fibrinolytic   and  placebo   which  has  significantly   showed   
reduction   in   death   as  well   as the   need    for   transfusion   in   all    
those   patients 
51 ,52.
  
ADVERSE   DRUG   REACTION 
Along   with   all  of   its   effects   it  may   cause    certain   
unwanted   effects. The  same   effects    of   tranexemic   acid that   
prevents   bleeding   may   lead    on   the  formation of  clot  that  could   
be   dangerous  warrenting medical   attention   in   such  situation 
73, 74, 75
 .  
The    possible   signs   and   symptoms    that  may   occur  leads  to   
 Head ache 
 Pain in  chest, groin, calf 
 Sudden   loss    of   co - ordination 
 Sudden  slurred   speech 
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 Sudden  vision   changes76, 77, 78 
 Sudden   shortness  of   breath 
 Weakness   or     numbness in   arm  / leg 
Other    bothersome   side  effects   which   may   be   present  are   
 Nausea   or  vomiting 
 Diarrhea 
 Dry   ejaculation and  watery  eyes79, 80. 
DRUG  INTERACTION 
Still  now   ,no   drug   interaction   has   been   reported
81 ,82, 83. 
OVERDOSE 
No    known   case  of   over  dosage   of   tranexemic  acid   is   still 
reported. Symptoms   of  overdosage   includes 
 Nausea 
 Vomiting 
 Hypotension 
CONTRAINDICATION 
36 
 
1. In  patient with acquired defective  colour vision as it prohibits 
measuring one   end   point  which    has   to  be  followed   as   a    
measure  of  toxicity 
2. In   patients   with    sub  arachanoid   hemorrhage   ,  sometimes    
cerebral edema   and cerebral   infarction    may   be   caused   by   
tranexemic   acid. 
3. Past  history   of  thromboembolism   episodes   or  with   active 
intravascular  clotting. 
4. Heart  disease, kidney   disease,  liver  disease. 
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CAESAREAN   SECTION 
 
FIGURE 8 CESAREAN SECTION DELIVERY 
Caesarean   section  is   the   most   commonly    performed 
operation   now a  days. There  is  a   steady   increase   in   the  rate   of   
ceasarean    section.  Ceaserean   delivery   is   defined  as   the   process  of   
delivery   of  the   foetus    after   the   period   of  viability   through   an 
abdominal   incision  and   uterine   incision   made   in   an  intact uterus.  
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SURGICAL   ANATOMY   OF CEASAREAN   SECTION 
DELIVERY 
THE   ABDOMINAL   WALL 
Knowledge    about   various   abdominal   wall layers    are    very 
much essential   for   the   surgeon    to enter    into the  abdominal   cavity   
as  well  as   to   ensure    maximum    safety  and   efficiency. Thus   the   
various   abdominal   wall   layers includes 
 Skin 
 Subcutaneous   layers  
Camper‟s   fascia 
Scarpa‟s  fascia 
 Musculo  aponeurotic   layer 
 Rectus   sheath 
 Rectus   abdominus    muscle 
 External   oblique   muscle 
 Internal    oblique   muscle 
 Transverse    abdominus   muscle 
 Transversalis   fascia 
 Peritoneum 
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BLOOD   SUPPLY 
SKIN 
The    skin   near   the midline    is   supplied   by  three   main   
arteries 
 Superior  epigastric  artery 
 Inferior  epigastric  artery 
 Superficial    epigastric  artery 
Almost   all   superficial   arteries    accompany   along   with 
cutaneous   nerves. 
The  superficial  epigastric   artery   run   from   the   femoral   artery 
towards  umbilicus   in  a   diagonal   course    in  the subcutaneous    
tissue.The   skin   along   the   flanks  are   supplied   from  the   branches  
of  the  branches   of   following  arteries 
 Intercostal   arteries 
 Lumbar   arteries 
 Deep  circumflex  iliac   vessels 
VENOUS  DRAINAGE  OF  SKIN 
Venous   system   is   the   network   of  veins   that   radiate from  
the  umbilicus.  The   veins   above   the   umbilicus  drains  into  the   
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lateral    thoracic   vein   and   axillary  vein which  in  turn  drains  into  
superior   vena  cava.The  veins  below   the  umbilicus   drains  via   
superficial epigastric   and   great   saphenous   vein   which  in  turn   
drains  into   femoral   vein   and  ultimately   into   inferior  vena  cava. 
ABDOMINAL  WALL   BLOOD  SUPPLY 
Main  arterial blood supply  include    
1. Superior   epigastric artery 
2. Musculo  phrenic artery 
3. Deep  circumflex   artery 
4. Inferior   epigastric  artery 
The   medial   part   of   whole   abdominal   wall   is  supplied    by 
epigastric   vessels   where   as    the   lateral   wall   is   supplied    from 
the   musculophrenic   and    deep   circumflex    iliac   vessel  along   with 
lower    intercostals   and   lumbar  vessels. 
The   linea    alba   present  in   the  midline   where   all  fascia   
converge   is   relatively   bloodless   and   hence    we   have    to be   very   
careful   in  case   of   low   midline incision   due   to   bloodless  field, 
The  healing  rate  is  lowered.The  superior   epigastric   artery   which  is   
the   terminal   branch   of internal   thoracic   artery   enters   into   rectus  
sheath   where   it  descends   behind  rectus  muscle   and   gets   
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anastomosed   with   that  of  inferior   epigastric   artery. It   supplies   the  
upper   central  part   of   the anterior   abdominal   wall  layer .The   
inferior epigastric   artery   which   is   the   branch   of   external  iliac  
artery   at  the   level   just   above  to  that   of   inguinal ligaments.  
It   enters   the   medial   end   of   deep   inguinal   ring   and runs   
upwards   where    it  pierces   the   transversalis  fascia  and  hence enters    
the   rectus   sheath  just   anterior  to   that   of  arcuate   line.  
  It ascends   and   gets   anastomosed    with   that   of   superior   
epigastric vessel.It  supplies   the   lower   central   part   of   the   anterior 
abdominal   wall   layers. 
The  deep   circumflex   iliac   artery    which   is  also   a  branch   of  the 
external  iliac   artery   at  the   level   of   inguinal   ligament  runs  upward  
and  laterally  towards    anterior   superior   iliac   spine  continuing   along  
with   that  of   iliac   crest.  
  It  mainly  supplies  the   lower   later   part  of  abdominal  wall.The  
two   posterior   intercostals   arteries,  four  lumbar  arteries   run between   
the   muscle   layers   and   supply   the  lateral   part   of  the  abdominal    
wall . The   main   vessel  that   is  subjected   to   injury   is  that   of   
epigastric   artery  that   too   particularly   when   the   muscle    splitting   
incision   is  made. 
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VENOUS  DRAINAGE 
The   venous   blood   forms   a  network   and   drains   above   into 
the   axillary   vein   and   from   below   to  the   femoral   veins.   A  few   
para  umbilical   vein   through  the    ligamentum teres   drain   into  the  
portal  vein.The   superior   epigastric,   inferior   epigastric    and   deep   
circumflex veins    drain   into  internal    thoracic   and    external   iliac   
veins.The   posterior   intercostals   veins   drain   into    azygos   and   
lumbar veins   drain  directly   into  that  of   inferior   vena  cava. 
BLOOD SUPPLY OF UTERUS 
 
FIGURE. 9 BLOOD SUPPLY OF UTERUS 
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The   main   artery   that  is   supplying    uterus   is  the  uterine   
artery.  There  are  two   uterine   artery   that   is  present   on  either   side  
of  the  uterus   and   this   uterine   artery   is  ultimately   the  branch   of 
anterior   division   of   internal    iliac  vessel. It   runs   medially   along  
the  cervix   crosses    the   ureter   at  the level   above  the   lateral   fornix   
that   is   2  cm   lateral   to  cervix  and  it   ascends   upwards   along   the  
lateral   wall   of   uterus   that  between   the   two   leaves   of   broad   
ligament    and   at  the    level   of   corneal   end   of  the  fallopian   tube, 
it  gets   anastomosed     with   that of  ovarian   artery. The   uterine   
artery    give   rise   to  anterior  and   posterior  arcuate   branches  along   
the   whole   length  of   uterus   it  usually   enter  transversely   into  the  
myometrium    of  the   uterus   from   where   it  gives   branches   as    
radial   branches. These   radial   branches  almost  anastomosing  that   of 
their counterpart radial branches. These before reaching the   endometrium  
tend to  supply the   basal layer   of   deciduas  by its   basal   branch  and   
make   their    entry    into   the   deciduas   by   spiral   arteries   that  are   
highly   tortuous. The   spiral   artery   reaches   their   maximum   spiraling   
at 20 weeks.  Later   on  as   pregnancy  passes   these  spiral    arteries    
become  straight   and   engorged   so  that  the   initial  blood   supply   of  
uterus  which  was    50  ml/min   increases  to    the   level  of   450  -600  
ml  /min  at   term. The   uterine   vein     which    is   engorged    in  
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pregnancy drain into   internal   iliac   veins. The   another   blood  supply 
is    from   the   ovarian    artery    which arises    from   abdominal  aorta    
below   the   level    of   renal    artery.  It   crosses   the   ureter   near    its  
origin   in  retro  peritoneal   space and   enters    into   the   suspensory   
ligament    of  ovary  .It   courses   along   the  underneath   fallopian   tube   
and  gets   anastomosed   with  that   of   uterine  vessels   at   the  level   of   
cornua   of  the  fallopian tube. The  ovarian   veins   that  is   arising   from   
pampiniform  plexus   at the   level   of   ovarian  hilum  drains   into   
inferior   vena  cava   on right  side    and  left  renal  vein   on  left  side. 
The   main  cause   for  blood  loss   during   caesarean   section  includes 
1) Injury  to  inferior  epigastric   vessels 
2) Injury   to   uterine   artery   by  lateral   extension   of  the   incision 
3) Upper   uterine   segment   incision 
4) Manual  removal   of  placenta 
It   is  well   documented   that   the   use   of  tranexemic  acid    
decreases   the   blood  loss  by  40  -50  %. 
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FIGURE. 9 BLOOD SUPPLY OF UTERUS 
VARIOUS   STUDIES 
 Study  conducted   by   Mayur  et  al   has    shown   that  usage   of  
tranexemic   acid   has   led    to  significant   reduction    in  blood   
loss  from  the    end  of  plancental  delivery   to  that  of   two  hours   
postpartum.
84
It   showed    that   the   amount  of   blood  loss   from 
the    end    of   LSCS  to   two   hours   postpartum    is   75.71  ml  in  
study   group versus   133.03  ml  in  that   of  control  group. It  also   
reduces    the amount   of  blood  loss   from   time   of   placental  
delivery   to  the end   of   LSCS  as  372.71  ml  in  study  group   
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where  as  it  was  469.70  ml   in  control  group.  No  obvious   
complications   were  reported. 
 Another   study  that  is   conducted   by  Tastsumoti  et  al   
randomized  case  control   trial   where   the   quantity  of   blood   loss  
was   assessed in   180  primipara   who are  divided  into   control  and  
study  group. This also   suggested   decrease    in  the   quantity   of  
blood   loss in the study  group. 
 Another   study   by  Yang H  et al  includes   dividing   subjects  into  
four   groups  as   follows
85 ,86.
 
Group  1:  Tranexemic  acid  1  gm   given  slow   intravenously 
Group  2:  Tranexemic  acid  0.5  gm  given  slow  intravenously 
Group  3:Aminomethyl   benzoic  acid  0.5  gm   given  intravenously 
Group  4:  No  treatment 
The  amount   of  blood  loss  is  calculated   from   the  time   of  
expulsion   of  placenta   and  two  hours   after   delivery.  The  total   
amount   of  blood  loss  calculated   were   243.3  ml,24.9ml, 
308.1ml,314.8  ml  respectively.   The   blood  loss   in    group  1  and  
group  2  were   significantly   less compared   to  that   of   group  3  and 
group  four.  The    incidence  of post  partum  hemorrhage   is  also   less 
in  group  1  and   group2.   Still   1 gm  of  tranexemic  acid   is  highly   
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efficacious  and   also  safe    in  the   aspect  of  reducing   postpartum    
blood  loss  in  these   subjects. 
 Afsar  et  al   conducted  a  randomized   study  in  90  primipara   
where  45   women  were  given  tranexemic  acid  and  45   women   
who  are  controls   receiving  placebo  . The  blood   loss  as  well  as   
hemotocrit  are  measured,  it  showed  the  blood    loss   in  
tranexemic acid   group   is 28.02ml  and  that   of   control  group  is  
that  of   37.12  ml  measured from  the   end  of   ceaserean   section   
to  two  hours   post  partum. No   complications   or  side  effects   was   
reported   in   either   of  the  groups. 
 Svanberget  al   studied  the   effect   of   intramuscular    usage  of 
tranexemic  acid   in  67   abruptio   placenta   patients   and   
concluded that   the   routine   use    of    tranexemic  acid   in   patients     
with    abruptio  placenta    can   reduce    the    perinatal   mortality.
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IN   MENSTRUAL   BLEEDING 
 Lethalyet  al   concluded    that    usage   of   tranexemic   acid   in 
patients    with    heavy   menstrual   bleeding   resulted    in   greater  
reduction   in   the    bleeding   compared   with   that   of   placebo 
significantly.
88 , 89.
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IN  CARDIAC  SURGERY 
 Brown   and   morgan  et  al   in  randomized   placebo   controlled  
trial   who  are   undergoing   coronary   artery   bypass   grafting   
surgery.  
90.
Tranexemic   acid   is   administerd   before    and   during   
the   operation  showed   they  are  highly   efficacious   in  reducing   
the   blood  loss  and   need   for   blood   transfusion. 
GYNAECOLOGY   SURGERY 
 Caglar  et  al   has  studied   effect   of   tranexemic  acid    in  patients 
undergoing    myomectomy   .It   has   reduced   peri operative   and   
post operative    bleeding   as  well  as  need   of  blood   transfusion   
has decreased.
91, 92, 93,94.
 
ORTHOPEDIC  SURGERY 
 Rajesparen  et  al   shows   the  effect   of  tranexemic  acid   in  total    
hip   replacement   it   has   reduced   post  operative   blood   loss. The 
treatment   was  not   associated   with   any   thromboembolic   
complication.
57,58.
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QUANTIFICATION  OF  BLOOD  LOSS 
Hemorrhage  in   obstetric   accounts   for  about   25 %  of   all   
maternal  deaths.  PPH  is  defined   as  any  bleeding   in  excesss   of   500  
ml   after  delivery.  Although   60 %  of  all  cases   of  PPH  can    be   
controlled   by active   management   of  third   stage   of  labour .  
Obstetric   hemorrhage  has    resulted    in   nearly   30 %  of   mortality   
or   maternal   death .   The   fifth   millennium   development   goal   to  
reduce   maternal   mortality   to  75  % by    2015   cannot    be   attained   
without   taking   into   consideration  PPH  in  developing   
countries.Clinicians   continue   to  rely  on   visual    estimates   to  
determine  the amount   of   postpartum   blood  loss  but   often   visual  
estimate   are  found   to  be   inaccurate  There   are   various   methods   
that   can   be   used in   the   estimate    of   blood  loss     during   the   
postpartum  period.
99 
VISUAL   ASSESSMENT 
The   observation   used in  the  visual    estimate   of   blood   is   
relatively straight   forward     and    hence   it   requires    no    
expenditure. 
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DIRECT AND  STANDARD  MEASURING  JAR 
This  approach  used  by  WHO  in  multicentric  trial of  usage  of 
misoprostal  in  active  management  of  third  stage  of  labour .The 
collected blood  was  poured  into  standard  measuring  jar  and  its   
whole  volume  was  measured. 
RUBBERISED  BLOOD  MAT  
In  Bangladesh  the  international  center  for  diarrhoeal   disease  
research  developed   a rubberized  blood  mat which  gets  saturated  with 
500  ml   of blood, with  flowered  plastic  on  one  side   and  rubber  on  
other  side . When after  delivery,the  mat   holds   maximum   of  500  ml   
of  blood . After  that  the  mat    begins   to  leak   into  plastic  and  then  
on  floor, which  signifies  post partum  hemorrhage. 
KELLY’S PAD 
The  continuum  of  care  project  which  was  implemented  in  
India  which is  a  rubberized  mat  called  as  kelly‟  pad  in order  to  
measure  the  blood loss. The  kellys pad  funnels  the  blood   into  a  
calibrated  bowl  where there  is  an  alert  line  at  about  500  ml.  This  
pad  is  washable  and sterilized  and  it  is  a   cost  effective  method. 
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GRAVIMETRIC  METHOD 
This  method  involves  weighing  sponges  before  and  after use. 
This method  requires  the   weighing  of all  soaked  pads  on  scale  and  
to subtract  the  known  weight  of  the  other  materials  used inorder  to 
determine  the  blood  loss. Inaccuracy   may  arise  at  several  levels due  
to lack  of  international  standardization  of  size  and  weight of  
guaze,sponges and  pads.
95,96,97,98. 
LABORATORY BASED  METHOD 
Alkaline hematin /acid hematin method: 
In  this  the  blood  is added to  a standardized  solution which 
converts hemoglobin  to  acid  hematin  or cyanmethemoglobin. This can  
be  measured  by a spectrophotometer  or  calorimeter. 
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FIGURE.10 PICTORIAL REPRESENTATION OF BLOOD LOSS 
SOILED  SANITARY  TOWEL   - 30 ML 
 
SOAKED  SANITARY  PAD  - 100ML 
 
53 
 
SMALL  SOAKED  SWAB  10 x10 cm         --   60ml 
 
LARGE  SOAKED   SWAB  45x45cm  ---350ml 
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FULL  KIDNEY  DISH  --500ml 
 
PPH  ON BED  ONLY --  1000 ml 
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PPH SPILLING ON FLOOR -2000 ml 
 
MAGNITUDE  OF  THE  PROBLEM 
The importance  of  knowing  the  amount  of  blood  loss  is  that  
this  is  the  leading cause  of  maternal  mortality  and  morbidity, when  
we   fail  to  recognize  the excessive  blood   loss   that  occurs  during  
child  birth ,if  early  intervention  are  not  initiated  obstetric  hemorrhage 
can lead to  death which  is the  worst  complication of pregnancy. 
SUGGESTED  EQUIPMENTS 
Various  equipments  that  are  being  suggested  to  measure  blood  
loss  include  
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1. Calibrated  under  buttock  drapes 
2. Scales to  weigh  the  soaked  items 
3. Dry weight  cards laminated  and are  attached  to  all scales  for 
measurement  of blood loss 
Formulas inserted  into  electronic  charting  system  which  can  
automatically  subtract  the  dry  weight  from  that  of  wet  weight  in  
standard  supplies  like  chux  and peripads. 
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MATERIALS AND METHODS 
PARTICIPANTS AND STUDY DESIGN 
Pregnant women undergoing LSCS in Coimbatore Medical College 
Hospital. It is a prospective randomized case control study commencing 
from August 2014 to August 2015. 
Sample size : 150.  
They are allocated in two  groups 
1. STUDY GROUP: Subject who receive Tranexemic acid 
2. CONTROL GROUP: Subject who did not receive Tranexemic acid. 
DETAILS OF THE STUDY 
INCLUSION CRITERIA 
Full term primigravida or multigravida with singleton pregnancy 
delivered by LSCS. 
EXCLUSION CRITERIA 
1) Medical or surgical problem involving     heart, liver, kidney, brain. 
2) History of thrombo embolic disorder. 
3) Pregnancy complications such as severe  pre-eclampsia , abruption 
placenta, placentaprevia, fibroid complicating pregnancy. 
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4) Any blood dyscrasia 
5) Allergy to Tranexemic acid. 
6) Multiple pregnancy,polyhydramnios. 
PARTICIPANTS  AND  STUDY  DESIGN 
Pregnant  women  undergoing  caesarean section in  Coimbatore  
medical  college hospital .It   is  a  prospective  randomized  case  control  
study  commencing  from August  2014   to  August  2015. Totally  150  
subjects  are  taken  for  study  according to the  inclusion  and  exclusion  
criteria protocol. 
ADMINISTRATION 
Tranexemic  acid  is  administered   15  to  20  minutes  before  
incision   in  a dosage  of  one  gram  intravenous  slowly  infused  over  5  
minutes. After  delivery  of  the  neonate  10 units  of  oxytocin   is 
administered  in  intravenous  drip. 
CONTROL  GROUP 
Tranexemic  acid  is  not  administered  oxytocin  10  units  is  
administered  in  intravenous  drip  after  the  delivery  of  the  neonate. 
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OBSERVATIONS 
CLINICAL  OBSERVATION 
1. VITAL SIGNS 
Heart  rate ,respiratory rate,blood  pressure  were  checked  immediately  
after placental  delivery  as  well  as  one  hour  and  two hour  after  birth  
of  the  neonate. 
2. BLOOD  LOSS 
The  blood loss  was  measured  from  the  period   of placental  
delivery  to  the end  of surgery  and  then  again  from  the  end  of  
operation  to  two  hours  postoperatively. The weight  and  volume  of  
blood  loss  was  estimated. 
3. Assess the contraction  of  uterus  and  placental  separation. 
4.  Neonatal  outcome  by apgar  scoring 
5. Any  obvious  side  effects  caused  by  administration  of  tranexemic  
acid. 
LABORATORY  EXAMINATION 
1. Complete  blood  count  with  platelet  count  done  before  delivery  
and  24 hours after  delivery. 
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2. Renal  function  test  and  liver  function  test   is done  before  
delivery  and second  day   post  operatively. 
3. Coagulation   profile   is  performed   before  and  after  delivery. 
QUANTIFICATION  OF  BLOOD LOSS: 
Blood  was collected   into  the  suction  container  after   the  
placental  separation, thus   excluding  the  collection  of  amniotic  fluid  
into  the  suction container, so  that  the  collected  blood  is  only  from  
that  has  occurred   after placental  delivery. 
  All  the  soaked  guage  pads  and  operation  table  sheets  are  
weighed. The measurement  in  two  different  period  one from  the  time  
of  placental separation  to  the  end  of  surgery .Next  one  from  the  end 
of  surgery  to  that  of  two  hours  postpartum. 
Quantity  of  blood  loss  =  (weight of  used  material  + weight  
      of unused  material) - (weight  of all  
      material  prior  to  surgery) +  
      volume collected in the suction  
      container after placental delivery. 
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Evaluation  of  effectiveness  of  tranexemic  acid  is  given  by 
1. Efficacy  of  the   drug 
2. Safety  of  the  drug. 
EFFICACY : 
Efficacy  is  given  by 
1. Amount of blood  loss 
2. The incidence  of PPH 
SAFETY: 
Safety  profile  is given by 
1. Monitoring  vital signs 
2. General side effects  with administration  of drug 
3. Labarotory  findings. 
SAMPLE  SIZE 
Control group : 75  subjects 
Study group  :   75  subjects 
Total  : 150  subjects 
They  are  allocated  into  two  groups 
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1. STUDY GROUP : subjects who receive  tranexemic acid 
2. CONTROL GROUP :subject   who  did  not  receive tranexemic 
acid 
All cases  included  in  both  groups  are   selected  according  to the  
inclusion and  exclusion  criteria  protocol  after  getting  consent. 
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RESULTS 
The prospective ramdomised  case control  study  conducted  in  
Coimbatore medical college  among 150 pregnant women  undergoing 
elective lower segment  caesarean  section from the  period  of  August 
2014 to August 2015 were all included in the study. 
From 150 subjects  75 received tranexemic acid  and 75  did not 
receive tranexemic acid 
TABLE 1 
DISTRIBUTION BASED ON PATIENT CHARACTERISTICSIN 
THE   STUDY 
 
STUDY 
GROUP 
(mean +/- SD) 
( n= 75) 
CONTROL 
GROUP 
(mean +/- SD) 
( n=75) 
P value 
AGE 26.33 +/- 4.14 25.56 +/-3.85 0.238 
Table 1. shows  that  the possible  confounding variable  age which  
is matched  effectively  in both  groups  of study  and control. 
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Mean age was 26.33  in study group  and  25.56  in control group  
with p value  as 0.238.  The difference  in  age  of  subject  of both group is  
not  satistically  significant. 
TABLE 2 
COMPARISON OF BLOOD LOSS FROM TIME OF PLACENTAL  
DELIVERY  TO  COMPLETION  OF SKIN CLOSURE 
BLOOD 
LOSS 
(ml) 
CASES CONTROL 
P 
value 
Placental 
delivery to 
end of 
surgery 
maximum minimum Median maximum minimum median 
<0.001 
320 250 300 960 350 380 
Thus table 2 shows  that the  mean blood loss from time of placental 
delivery to completion of caesarean section ,there is a median loss of 300 
ml  whereas  it is 380 ml in control group with p value  of <0.001 which  is 
statistically significant blood  loss   in both  study and control group. 
Patients who received  tranexemic acid has nearly 80 ml of blood loss  less 
than those of patients who did not receive tranexemic acid. 
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GRAPH  1 
BAR DIAGRAM SHOWING COMPARISON OF BLOOD LOSS 
FROM THE TIME OF   PLACENTAL DELIVERY  TO END OF 
SURGERY 
 
Now coming on to comparison of blood loss from the  end of  
caesarean section to  two hours postpartum  is as follows  as given  in the 
table 
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TABLE 3 
COMPARISON OF BLOOD LOSS FROM THE END OF SURGERY 
TO   TWO HOURS POSTPARTUM 
Blood 
loss (ml) 
cases Control Mean P value 
End of 
surgery 
to 2 hrs 
post op 
max min median max Min median 
30 <0.001 
50 30 40 120 50 70 
 
Thus table 3 reveals to us that the median blood loss from time of 
end of caesarean to two hours post operative period in study group  is 40 
ml compared to70ml in the control group with the mean difference of 30 
ml  with highly significant statistical difference  among blood loss  in both 
study and control group . Thus,patients on tranexemic acid had 30 ml of 
blood loss less compared  to that of control group who did not receive 
tranexemic acid. 
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GRAPH 2 
BAR DIAGRAM SHOWING COMPARISON OF BLOOD LOSS 
FROM END OF   SURGERY TO 2 HOURS POSTPARTUM 
 
             Graph demonstrates the amount of blood loss from the end of 
surgery to two hours postpartum among both cases and control. 
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TABLE 4 
COMPARISON OF TOTAL BLOOD LOSS FROM THE END OF 
PLACENTAL DELIVERY TO TWO HOURS POSTPARTUM 
Blood loss cases 
(median) 
control 
(median) 
Mean 
difference 
P value 
Total(ml) 340 450 110 <0.001 
Thus the blood loss starting right from the end of caesarean section 
to that of two hours of postpartum  shows of median  of 340 ml  blood 
lossin cases and 450 ml blood loss in control group. Thus accounting for 
110 ml of blood loss less in the patients receiving tranexemic acid as such  
which the p value of <0.001which shows that it is highly significant  
statistical difference  in blood loss among  both study and control group. 
Thus patients who receive tranexemic acid before  surgery  has 110ml less 
blood loss compared to the patients who did not receive tranexemic acid. 
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GRAPH 3 
BAR DIAGRAM SHOWING TOTAL BLOOD LOSS FROM THE 
END OF PLACENTAL DELIVERY TO THE END OF TWO 
HOURS POST PARTUM 
 
           The graph demonstrates the total blood loss from the end of 
placental delivery to two hours post partum. 
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TABLE 5 
COMPARISON OF BLOOD LOSS MORE THAN 500 ML AMONG 
BOTH THE GROUPS 
Blood 
loss>500ml 
cases control P value 
present 0 0 7 9.33% 
0.013 Absent 75 100% 68 90.67% 
Total 75 100 % 75 100% 
 
Table 5 shows incidence of blood loss more than 500ml  among  
both cases and control .the p value obtained  here is 0.013 which was 
statistically significant. The incidence of PPH is more in the control group 
compared to the study group  which had no incidence of PPH 
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GRAPH 4 
BAR DIAGRAM SHOWING COMPARISON OF BLOOD LOSS 
MORE  THAN 500 ml  AMONG BOTH THE GROUPS 
.   
 The graph demonstrates the incidence of PPH among both the groups 
which is obviously nil in the study group. 
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TABLE 6  
COMPARISON OF THE DIFFERENCE IN HAEMOGLOBIN  % 
POST OPERATIVELY AMONG BOTH THE GROUPS 
HB cases control 
Mean 
differe
nce 
P 
value 
After 
surgery 
maximum minimum median Max min median 
0.20 <0.001 
1.2 0.2 0.60 3.9 0.2 0.80 
This Table 6  shows the Hb% difference which is given in median 
for the group. Given tranexemic acid came as 0.60 and for the group not 
given tranexemic acid came as 0.80 and the difference in Hb % between 
two groups is 0.20 with  p value of <0.001  which is highly significant 
statistically. 
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GRAPH 5 
PIE CHART SHOWING THE DIFFERENCE OF HEMOGLOBIN 
AMONG BOTH THE GROUPS 
 
 
This  graph demonstrate the mean hemoglobin difference is more in the 
control group. The hemoglobin  difference is less among study group in the 
post operative period. 
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TABLE 7 
COMPARISON OF VITAL SIGNS AMONG BOTH GROUPS –
POST OPERATIVELY 
Vital 
signs 
Cases control 
P value 
mean SD mean SD 
HR 90.02 4.23 91.41 3.86 0.038 
RR 14.5 1.45 15.16 1.62 0.014 
Table 7 shows that heart rate (HR) and respiratory rate (RR)  in both 
the groups does not show statistical significant difference.  
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FIGURE 6 
BAR DIAGRAM SHOWING COMPARISON OF VITAL SIGNS 
AMONG BOTH THE GROUPS 
 
           Coming on to effect of respiratory rate and heart rate , there is no 
statistical significance among both the groups.
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TABLE 8 
COMPARISON OF BLOOD PRESSURE MEASUREMENT 
AMONG BOTH THE GROUPS 
BP 
STUDY CONTROL P 
VALUE N % N % 
SBP 
100 15 20 15 20 
0.858 110 33 44 36 48 
120 27 36 24 32 
DBP 
60 0 0 6 8 
0.040 70 33 44 28 37.33 
80 42 56 41 54.67 
Thus the systolic blood pressure (SBP) and diastolic blood pressure 
(DBP) does  not show any significant difference  between both the groups. 
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TABLE8 
BAR DIAGRAM SHOWING COMPARISON OF BLOOD 
PRESSURE AMONG BOTH THE GROUPS 
 
Among both the groups there is no significant difference in both systolic  
and diastolic blood pressure intra operatively as well post operatively. 
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TABLE 9 
COMPARISON OF APGAR SCORE AMONG BOTH THE 
GROUPS 
APGAR 
SCORE 
CASES CONTROL 
P VALUE 
N % N % 
7/10 1 1.33 7 9.33 0.29 
8/10 74 98.67 68 90.67 
Table 9  reveals that apgar score  at 1 minute in newborn  in both the 
groups as the p value as  0.29 which is  not satistically significant. 
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FIGURE 8 
BAR DIAGRAM SHOWING COMPARISON OF APGAR SCORE 
AMONG BOTH THE GROUPS 
 
     There is no obvious variation in the apgar score among both the groups. 
The neonatal outcome remains the same among both the groups. 
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TABLE 10 
COMPARISON OF ADVERSE DRUG REACTION IN BOTH THE 
GROUPS 
ADVERSE 
REACTIONS 
CASES CONTROL 
P VALUE 
N % N % 
NAUSEA 15 54.55 9 52.94 
0.934 
VOMITING 12 45.45 8 47.06 
OTHERS - - - - 
- 
THROMBOSIS - - - - 
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FIGURE 9 
BAR DIAGRAM SHOWING ADVERSE EFFECTS AMONG BOTH 
THE GROUPS 
 
Table 10. shows the adverse side effects  in the study group of 
administration of tranexemicacid  has nausea and vomiting among 15 and 
12 subjects respectively. No other complications as well as no evidence of 
thrombosis in this study group. Whereas in control group  the incidence of 
nausea and vomiting is 9 and 8  respectively. No other significant adverse 
effect seen. This gives the p value of 0.934  which is not statistically  
significant . Thus it can be concluded that the incidence of side effects 
profile  is not  increased  among the tranexemic acid group compared to 
the control where tranexemic acid  is not given. As there is no incidence of 
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thrombosis among both the groups ,the fear of main side effect of 
tranexemic acid as thrombosis  can be left apart according  to this present 
study. 
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DISCUSSION 
Tranexemicacid  is an anti fibrinolytic agent. Tranexemic acid 
literally dismiss the dissolution of hemostatic fibrin by plasmin due to its 
anti fibrinolytic effect. More over during the placental delivery  the 
fibrinogen and fibrin gets degraded rapidly and simultaneously 
plasminogen activator as well as fibrin degradation products increases as 
the fibrinolytic system gets activated. It is found that this fibrinolytic 
activity which has started immediately after placental delivery can last for 
nearly 6 -8 hours post partum resulting in more blood loss.Thus,taking this 
into account,we have decided to take   tranexemic acid which  is an anti 
fibrinolytic agent for our study.  
Tranexemic acid actively binds at the lysine receptor  binding site  
of fibrin and hence it stabilizes fibrin and prevents it undergoing 
fibrinolysis. Tranexemic acid also inhibits plasminogen conversion into 
plasmin by inhibiting plasminogen activator . Thus tranexemic acid is used 
in treatment  of  reducing  blood loss for many years. 
From our study it has been evident that tranexemic acid significantly 
reduces the blood loss from the time of placental delivery to that of 2 hours 
postpartum..The values that are being obtained  in the study group is 340 
ml and in the control group is 450 ml with a median blood loss of 110 ml 
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which gives  the p value of <0.001 which is highly satistically significant 
difference. Thus, the blood loss is nearly  35 % less than in the control 
group  which is significant. The blood loss from  the time of placental 
delivery to end of  caesarean section is 350 ml in study group and 380 ml 
in control group giving p value  as <0.001  which  is statistically  
significant. 
 The blood loss from the end of caesarean section to two hours  
postpartum as given in the study group is 40 ml and in the control group is 
70 ml with a p value of <0.001 which is once again statistically significant. 
Thus, tranexemic acid administration reduces the blood loss right  
from   the end  of placental delivery to two hours postpartum. In case of 
calculating  blood loss >500 ml in  both the groups  gives us the value as 
follows. There is no evidence of blood loss >500 ml in the  study group 
where as the incidence of blood loss  more than 500 ml  in control group is 
7 giving us  the impression  that  blood loss is more in the group who are 
not administered tranexemic acid  prior to surgery and the p value that is 
obtained is 0.013 which is significant satistically. The list extends  that the 
group has been administered  tranexemic acid showed  the post operative  
hemoglobin  difference  less compared to the group  not administered with 
tranexemic acid  with p value of <0.001. hence the efficacy  of using 
tranexemic  acid  is proven  as it not only reduces  blood loss and decreases  
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incidence of post partum haemorrhage  as well as improves  the 
hemoglobin  difference. 
Coming on to vital parameters both the study and control group  
does not  show any statistical difference in heart rate, respiratory rate, 
blood pressure. Hence tranexemic acid can be safely given without any 
significant changes in vital parameters. 
In view of Apgar score administration  of tranexemic acid  has no 
effects  on outcome  difference  in  the Apgar among both the group.In 
view of adverse effects  among the tranexemic acid  administered  group  
does not  show any significant difference compared with that of control 
group. There is no evidence of  increased risk  of thrombosis in the present 
study. 
 Afshan shahid and Ayesha khan conducted  a randomized  double 
blind placebo controlled trial  and concluded  that  tranexemic acid  
significantly  reduced  the  amount of blood loss during  the lower segment 
caesarean section but it  did not reduce the blood loss  significantly  after 
the caesarean section. Its use  was not associated  with  any side  effects  or 
complications like thrombosis. Tranexemic acid can be safely and 
effectively used  in women who are undergoing lower segment caesarean 
segment in order to reduce intra operative blood loss. 
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Anne sophie ducloy bouthors et al conducted a study to determine 
administration of high dose of tranexemic acid at the time of diagnosis of 
post partum hemorrhage  Could reduce blood loss and finally demonstrate  
that high dose of tranexemic acid can reduce blood loss and maternal 
morbidity in women with post partum hemorrhage. The side effects 
observed in this study was only mild and transient. However further study 
is required  to investigate  further about  the action of tranexemic acid in 
reducing post partum hemorrhage. 
Gohe l Mayur, patel purvi et al conducted a study to know the 
efficacy and safety of tranexemic acid in reducing blood loss during and 
after the lower segment caesarean section and concluded that tranexemic 
acid significantly reduces the amount of blood loss during and after 
caesarean section and they are not associated with any side effects or any 
complications and can be safely used in caesarean section. 
Panagio tespeitsidis et al conducted similar study to evaluate the 
efficacy and safety of tranexemic acid in the management of obstetric 
hemorrhage, so that tranexemic acid can be used for prevention as well as 
treatment for postpartum hemorrhage and concluded that the tranexemic 
acid is highly effective in reducing the amount of blood loss after delivery 
which may be either caesarean section or vaginal delivery as well as 
decreases the need for blood transfusion. 
 87 
 
 Haleemashakur et al famous THE WOMEN trial (World Maternal 
Anti fibrinolytic trial) and the main aim here is intention to treat basis 
which showed significant reduction in blood loss.  
H. Abdel Aleem et al conducted similar study to evaluate the 
effectiveness of tranexemic acid in reducing blood loss in elective 
caesarean section and found positive   results as it  may be of much 
benefits for anaemic women as well as women who needs blood 
transfusion. 
Sekhavat et al concluded the same results as tranexemic acid  
statistically reduces blood loss from the end of caesarean section to two 
hours post partum and its use  is not associated  with any side  effects or 
complications. 
 TarabrinGalich has done a similar study to evaluate blood loss 
during caesarean  section with tranexemic acid and found that blood loss is 
significantly reduced to nearly 60 %. 
Mehmet B Senturk  et al conducted a study to assess the efficacy 
and safety of an intravenous tranexemic acid to reduce bleeding during 
child birth and concluded and confirmed that tranexemic acid is effective 
in reducing blood loss with no worries about  thrombosis. 
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CONCLUSION 
1. Tranexemic acid is highly effective in significantly reducing the 
blood loss during as well as after the lower segment caesarean 
section. 
2. Tranexemic acid usage has not resulted in excess blood loss 
exceeding more than 500 ml and hence the incidence of post partum 
hemorrhage among the tranexemic acid group is minimal. 
3. Tranexemic acid administration is not associated with any adverse 
drug reactions. 
4. There is no risk of thrombosis among the users of tranexemic acid. 
5. Fetal outcome as given by apgar score is not affected by the usage of 
tranexemic acid. 
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SUMMARY 
 This study was carried out to find whether the usage of tranexemic 
acid prior to surgery to all patients undergoing elective lower segment 
caesarean section in Coimbatore medical college hospital during the period 
of August 2014 to August 2015 has resulted in reduction in blood loss 
during and after caesarean section 
1. The confounding factor age is comparable in both the groups. 
2. Study group showed marked decrease in amount of blood loss from 
the time of placental delivery to the end of caesarean section around 
80 ml compared to that of control group. 
3. Similar scenario is that the blood loss from the end of caesarean 
section to two hours postpartum in the study group is 40 ml less than 
in the control group. 
4. The amount of blood loss from the time of placental delivery to that 
of two hours postpartum among the study group is 110ml less  
compared to that of control group. 
5. Tranexemic acid has significant difference in hemoglobin difference 
post operatively as blood loss is decreased compared to study group. 
6. There is no significant difference in vital parameter in both the 
groups. 
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7. There is no significant difference in Adverse effects in both the 
groups. 
8. There is no significant difference in Apgar score in newborn in both 
the groups. 
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PROFORMA 
NAME                                                                      IP.NO 
AGE                                                                         DOA 
OCCUPATION                                                       DOD 
ADDRESS 
 
 
DIAGNOSIS 
PRESENTING COMPLAINTS 
Amenorrhea 
Labour pains                                           :   yes /no 
Leaking per vagina                                 :   yes  /no 
Bleeding  per  vagina                               :  yes /no 
Appreciates  foetal  movements  well     :  yes /no 
History  suggestive  of pre eclampsia     :  yes /no 
History  suggestive of  anaemia               : yes /no 
  
  
 
MENSTRUAL  HISTORY: 
Age  of  menarche: 
Last  menstrual  period: 
Expected  date  of  delivery: 
Cycles                                                  : regular  /irregular 
MARITAL  HISTORY: 
Married  since: 
Consanguious  /non consanguious  marriage: 
OBSTETRIC  HISTORY; 
Gravida 
Para 
Living 
Abortion 
HISTORY  OF  PREVIOUS  PREGNANCY: 
PAST   HISTORY: 
Hypertension                       yes/no 
Diabetes                                yes/no 
  
 
Bronchial asthma                  yes/no 
Tuberculosis                         yes/no 
Epilepsy                               yes /no 
Rheumatic  heart  disease    yes/no 
Hypothyroid                      yes/no 
Previous blood transfusion 
PERSONAL  HISTORY: 
Diet: 
Appetite: 
Bladder/bowel  habbits: 
GENERAL  EXAMINATION 
Build:    
Nourishment: 
Pallor: 
Pedal  edema: 
Height: 
Weight: 
  
 
BMI: 
Pulse  rate: 
Blood   pressure: 
Breast: 
Spine: 
Thyroid: 
SYSTEMIC  EXAMINATION 
Cardiovascular   system: 
Respiratory  system: 
Central  nervous  system: 
Obstetric  examination: 
Inspection : 
Palpation: 
Auscultation: 
Per  vaginal  examination: 
 
  
 
INVESTIGATIONS 
BLOOD HB 
URINE ROUTINE 
HIV 
HBsAg 
RBS 
Blood urea 
Serum  creatinine 
Liver function test: 
Coagulation profile: 
Indication  of  caesarean  section: 
Time of  givingtranexemic acid: 
Time of skin  incision: 
Baby details: 
 Single term alive  ----------  baby 
 Birth  weight: 
  
 
 Time: 
Apgar  score  at 1 min:                   at  5  min: 
After   delivery  of  placenta: 
 Dry  mop  weight:  (A) 
After soakage weight(B) 
Total  blood loss:  (B)   -  (A ) =QUANTITY  OF  BLOOD  LOSS : 
 
 
 
 
 
 
 
 
  
 
Before 
Delivery
After 
Delivery
Before 
Delivery
After 
Delivery
SBP(mm of 
Hg)
SBP(mm of 
Hg)
DBP(mm of 
Hg)
DBP(mm of 
Hg)
HR RR
1 Aparna 10264 26 G2P1L1 9.20am 9.40am 300 40 340 10.2 10 0.2 120 110 80 70 88 16 8/10 - - -
2 Shakila banu 11157 22 G2P1L1 9.30am 9.50am 250 40 290 11.4 10.8 0.6 11o 120 80 80 84 14 8/10 - - -
3 Mallika 10258 33 G2P1L1 9.25am 9.41am 280 40 320 10.4 9.8 0.6 120 110 70 80 88 16 8/10 - - Nausea
4 shubha 10412 24 G2P1L1 9.05am 9.26am 300 40 340 11.8 11.2 0.6 110 110 80 70 90 15 8/10 - - -
5 Kalaivani 13767 25 G2P1L1 10.45am 11.00am 280 50 330 10.2 10 0.2 120 120 70 70 82 14 8/10 - - Vomiting
6 Raabi 17430 23 G2P1L1 9.30am 9.50am 300 40 340 10.4 10 0.4 120 110 70 80 86 16 8/10 - - -
7 Saranya 18327 25 G2P1L1 9.40am 10.00am 280 40 320 10.8 10 0.8 110 100 80 80 92 15 8/10 - - Nausea
8 Victoria 18317 21 G2P1L1 9.10am 9.27am 300 30 330 11 10.8 0.2 120 120 80 70 84 16 7/10 - - -
9 Shajira 19165 28 G3P2L2 9.25am 9.42am 280 50 330 10.8 10.4 0.4 110 100 80 80 90 15 8/10 - - -
10 Gowri maheshwari 20864 28 G2P1L1 10.05am 10.28am 250 50 300 10.8 10.2 0.6 110 120 70 70 80 12 8/10 - - -
11 Punitha 22481 29 G3P1L1A1 10.25am1 10.42am 300 40 340 10 9.8 0.2 110 100 80 70 86 16 8/10 - - -
12 Saranya 21448 25 G2P1L1 9.35am 9.55am 300 30 330 12 11.4 0.6 120 120 70 80 88 14 8/10 - - -
13 Kani mozhi 24208 28 G2P1L1 10.25am 10.41am 280 40 320 10.2 9.8 0.4 110 110 80 80 82 2 8/10 - - Vomiting
14 Rekha 24839 21 G2P1L1 10.35am 10.57am 300 40 340 10 9.8 0.2 110 120 80 70 88 16 8/10 - - Nausea
15 Eswari 25531 33 G4P1L1A2 9.30am 9.47am 280 50 330 10.8 10 0.8 120 110 70 80 90 14 8/10 - - -
16 Subha 26364 24 G2P1L1 9.30am 9.45am 300 40 340 10.4 10.2 0.2 110 120 80 80 86 15 8/10 - - -
17 Sunitha 26157 29 G3P1L1A1 9.05am 9.27am 280 40 320 10 9.4 0.6 120 100 80 80 90 12 8/10 - - Vomiting
18 Susila 26175 28 G2P1L1 9.00am 9.22am 300 30 330 10 9.8 0.2 110 110 70 80 92 16 8/10 - - -
19 Saranya 27213 22 G2P1L1 9.10am 9.30am 320 40 360 10 9.2 0.8 110 120 80 70 90 14 8/10 - - Vomiting
20 Menaga 27265 29 G2P1L1 10.10am 10.25am 300 40 340 11.2 10.4 0.8 110 120 70 70 84 15 8/10 - - -
Age 
(years)
BP
vitals
Blood Loss (ml) HB % (gm/dl)
APGAR
Use  of 
additional 
oxytocins
Complication Side effect
Placental 
delivery to 
end of CS
End of CS to 2 
hrs 
Postpartum
Total
Before 
Delivery
24 Hrs 
After  
delivery
Fall in Hb% 
(gm/dl)
S. No. NAME IP No Parity
Time of 
giving 
tranexemic 
acid
Time of 
giving skin 
incison
MASTER CHART WITH TRANEXEMIC ACID 
 
 
  
 
  
21 Nirmala 28280 28 G2P1L1 11.25am 11.38am 280 50 330 10.8 10.4 0.4 120 110 80 70 94 12 8/10 - - -
22 Kalaivani 28549 21 G2P1L1 9.25am 9.37am 280 40 320 11.2 10.6 0.6 120 110 80 80 88 16 8/10 - - Nausea
23 Saraswathi 27610 20 G2P1L1 9.20am 9.37am 300 30 330 10.8 10 0.8 110 100 70 70 92 12 8/10 - - -
24 Sakina 30228 30 G3P2L2 9.15am 9.30am 300 40 340 10 9.8 0.2 120 110 80 80 94 14 8/10 - - -
25 Nirmala 29641 20 G3P1L1A1 9.30am 9.43am 300 40 340 10.4 9.8 0.6 110 100 80 70 82 12 8/10 - - -
26 Vennila 30440 26 G2P1L1 9.30am 9.47am 280 40 320 10.8 10 0.8 100 110 80 80 88 14 8/10 - - Nausea
27 Valli 31728 26 G2P1L1 9.30am 9.45am 300 30 330 10.4 10.2 0.2 110 120 70 80 86 14 8/10 - - -
28 Rabiya 31294 24 G2P1L1 9.30am 9.50am 320 40 360 10.4 9.8 0.6 120 110 80 80 96 15 8/10 - - Vomiting
29 Priya 33052 24 G2P1L1 9.15am 9.33am 300 30 330 10.2 9.6 0.8 110 100 70 70 86 16 8/10 - - -
30 Sangeetha 34682 25 G2P1L1 9.25am 9.40am 320 30 350 11.4 10.8 0.6 120 120 70 80 90 14 8/10 - - Nausea
31 Ranganayaki 33782 22 G2P1L1 10.30am 10.50am 300 40 340 12 11.4 0.6 110 120 80 70 94 12 8/10 - - Vomiting
32 Saranya 35701 27 G3P2L1 10.45am 11.04am 280 50 330 13 12.8 0.2 120 110 70 80 84 16 8/10 - - -
33 Pauvul rani 37045 31 G2P1L1 9.30am 9.50am 300 40 340 12 11.2 0.8 110 120 80 70 90 14 8/10 - - -
34 Saradha 36868 35 G3P2L2 10.30am 10.52am 300 50 350 9.8 9 0.8 100 110 70 70 98 16 8/10 - - Nausea
35 Manju 37346 25 G2P1L1 9.15am 9.32am 280 50 330 10.4 10 0.4 120 110 80 80 94 12 8/10 - - -
36 Priyanka 36104 24 G2P1L1 9.20am 9.47am 300 30 330 10.8 10 0.8 110 110 70 70 86 16 8/10 - - Vomiting
37 Sujitha 37082 33 primi 9.15am 9.33am 300 40 340 12 11.6 0.4 120 100 80 70 90 16 8/10 - - -
38 Vigini 38262 25 G2P1L1 9.10am 9.25am 320 30 350 10 9.4 0.6 110 120 70 80 96 14 8/10 - - -
39 Jerina begum 32824 35 G2P1L1 9.50am 10.10am 300 40 340 10 9.2 0.8 120 110 80 70 94 16 8/10 - - -
40 Kalaivani 36849 29 G2P1L1 10.10am 10.28am 280 50 330 10.2 10 0.2 110 110 70 80 90 14 8/10 - - -
41 Nirmala 37526 24 G2P1L1 9.25am 9.45am 300 303 330 10.8 0.2 0.6 120 100 80 70 98 16 8/10 - - Nausea
42 Radhika 39479 25 G2P1L1 10.40am 11.05am 310 40 350 10.8 9.8 1 110 100 80 80 90 12 8/10 - - -
43 Sindhu 37879 27 G3P1L1A1 9.50am 10.12am 300 30 330 12 11.4 0.6 110 120 70 80 86 16 8/10 - - Nausea
44 Muruga lakshmi 39680 21 primi 10.15am 10.35am 280 40 320 10.8 10 0.8 120 110 80 80 82 14 8/10 - - -
45 Shanthi 39291 27 G3P1L1A1 9.10am 9.33am 300 40 340 10.8 9.8 1 110 110 80 70 90 15 8/10 -- - -
46 Meena 61159 25 G2P1L1 9.05am 9.23am 300 30 330 11 10.8 0.2 120 110 70 70 88 12 8/10 -- - -
47 Priyadharshini 62484 27 G2P1L1 9.20am 9.40am 300 40 340 10.9 10 0.9 1101 100 80 70 90 14 8/10 - - Nausea
  
 
 
48 Ranjitha 62896 23 G2P1L1 9.25am 9.47am 320 30 350 10.6 10.4 0.2 120 110 70 80 92 16 8/10 - - -
49 Pushpa 59439 26 G2P1L1 9.45am 10.05am 300 40 340 11 10.1 0.9 110 120 80 90 90 14 8/10 - - Vomiting
50 Valiammal 64252 33 G2P1L1 9.10am 9.33am 280 50 330 11.8 10.6 1.2 120 110 80 70 94 16 8/10 - - -
51 Jaya lakshmi 64630 33 G5P1L1A3 9.00am 9.18am 300 40 340 10.8 10 0.8 110 120 70 80 90 12 8/10 - - -
52 Mariammal 64414 27 G2P1L1 10.00am 10.23am 320 30 350 12.8 12 0.8 120 110 80 70 88 14 8/10 - - Vomiting
53 Meghala 58624 23 G2P1L1 9.50am 10.12am 300 40 340 11 10.8 0.2 110 120 70 80 92 16 8/10 - - -
54 Aswathi 66782 18 primi 10.00am 10.20am 280 50 330 12.4 11.4 1 120 110 80 70 92 14 8/10 - - Nausea
55 Poongodi 67753 29 G2P1L1 9.35am 9.56am 300 30 330 10.81 10 0.8 110 120 70 80 90 16 8/10 - - -
56 Manju 68030 24 G2P1L1 9.25am 9.43am 300 40 340 10.8 10 0.8 110 120 80 70 88 16 8/10 - - Nausea
57 Vanitha 67794 23 G2P1L1 10.45am 11.08am 310 40 350 11 10.4 0.6 120 100 70 80 90 14 8/10 - - -
58 Lokamani 70415 35 G2P1L1 9.25am 9.42am 290 40 330 10.4 9.8 0.6 110 100 80 70 94 16 8/10 - - -
59 Nadhiya 70622 27 G2P1L1 9.30am 9.47am 300 30 330 10.8 10.4 0.4 120 110 70 80 90 12 8/10 - - Vomiting
60 Lokanayaki 71805 22 G2P1L1 12.05pm 12.23pm 280 40 320 13.2 12.8 0.4 110 110 80 70 98 14 8/10 - - -
61 Ramya 72111 23 G2P1L1 9.25am 9.40am 300 40 340 12.4 11.8 0.6 120 120 70 80 96 16 8/10 - - -
62 Sathya 72912 20 G2P1L1 9.15am 9.33am 310 30 340 11 0.8 0.2 100 110 80 80 92 14 8/10 - - Nausea
63 Mariammal 73837 32 G2P1L1 9.30am 9.47am 300 50 350 12.4 11.8 0.6 110 120 70 80 90 16 8/10 - - -
64 Renuga devi 76040 25 G3P1L1A1 9.45am 10.05am 310 30 340 10.9 10.4 0.5 120 110 80 70 94 14 8/10 - - -
65 Sathya 75867 23 G2P1L1 10.45am 11.05am 300 40 340 10.8 10 0.8 110 120 70 80 90 16 8/10 - -
66 Sudha 76928 24 G3P1L1A1 9.10am 9.28am 300 30 330 11.8 10.9 0.9 120 110 70 80 94 15 8/10 - - -
67 Manjula 77380 33 G2P1L1 9.25am 9.42am 280 50 330 9.8 9.4 0.4 110 120 80 70 98 14 8/10 - - -
68 Suseela banu 76930 27 G2P1L1 10.10am 10.28am 300 30 330 11.4 10.8 0.6 120 110 80 80 90 16 8/10 - - Vomiting
69 Ramya 78139 24 G2P1L1 9.10am 9.33am 290 40 330 10.4 10 0.4 110 120 70 80 96 16 8/10 - - Nausea
70 Rajathi 78091 25 G2P1L1 9.15am 9.38am 310 30 340 12.2 11.8 0.4 120 110 80 70 92 14 8/10 - - -
71 Uma maheshwari 80225 33 G3P1L1A1 9.00am 9.20am 300 40 340 12 11.4 0.6 110 120 80 80 86 16 8/10 - - -
72 Indira 79375 27 G5P1L1A3 9.55am 10.16am 280 50 330 10.4 10 0.4 120 110 70 80 90 14 8/10 - - Nausea
73 Velumani 80421 24 G2P1L1 9.10am 9.29am 300 40 340 11.2 10.8 0.4 110 120 80 70 88 16 8/10 - - -
74 Selvi 80931 27 G2P1L1 9.10am 9.29am 280 40 320 13 12.2 0.8 120 100 70 80 94 12 8/10 - - -
75 Kalavathi 80549 36 G2P1L1 9.25am 9.43am 300 30 330 12.8 11.9 0.9 110 100 80 80 98 14 8/10 - - Vomiting
  
 
Before 
Delivery
After 
Delivery
Before 
Delivery
After 
Delivery
SBP(mm 
of Hg)
SBP(mm 
of Hg)
DBP(mm 
of Hg)
DBP(mm 
of Hg)
HR RR
1 Namagiri 11212 28 G3P1L0A1 - 9.38am 380 50 430 12 11 1 110 110 80 70 86 14 8/10 - - -
2 Kalpana 12072 24 G2P1L1 - 9.30am 360 70 430 12.2 11.4 0.8 120 110 80 80 88 18 8/10 - - -
3 Sumathi 12503 27 G2P1L0 - 9.33am 380 80 460 11.8 10.4 1.4 110 100 80 70 90 16 7/10 - - -
4 Shanthi 16503 21 G2P1L1 - 11.52am 350 70 420 11.8 10.8 1 120 110 70 80 96 14 8/10 - - -
5 Balamani 18316 25 G2P1L1 - 9.47am 380 70 450 12.2 11.4 0.8 110 120 80 70 94 12 8/10 - - Nausea
6 Vimala 19116 26 G2P1L1 - 10.43am 390 60 450 13.2 11.2 2 120 100 70 80 98 14 8/10 - - -
7 Najimunisha 19150 28 G3P2L2 - 9.33am 400 70 470 12.8 10.9 1.9 110 120 80 70 96 16 8/10 - - -
8 Manju 18481 21 G3P2L2 - 10.35am 390 50 440 14 12.4 1.6 120 110 80 70 90 14 8/10 - - -
9 Umavathi 20053 23 G2P1L1 - 9.40am 900 120 520 13.4 9.8 3.6 120 100 80 60 98 18 7/10 oxytocin PPH -
10 Maharnisha 23899 23 G2P1L1 - 10.40am 430 70 500 12.8 11.8 1 110 120 70 70 90 16 8/10 - - -
11 Jaffar nisha 24007 27 G2P1L1 - 9.37am 400 60 460 12.4 11.8 0.6 120 110 80 80 92 14 8/10 -- - -
12 Radha 25582 31 G2P1L1 - 10.17am 380 80 460 11 10.2 0.8 110 120 70 80 96 16 8/10 - - vomiting
13 Vijayalakshmi 24855 34 G2P1L1 - 11.10am 380 60 440 10.8 9.6 1.2 120 110 80 80 88 15 8/10 - - -
14 Jayashree 26481 22 G2P1L1 - 10.43am 350 80 430 11 10.2 0.8 110 120 80 80 92 12 8/10 - - -
15 Saranya 27213 22 G2P1L1 - 9.33am 380 70 450 11.8 11 0.8 120 110 70 80 94 14 8/10 - - -
16 Ranjitha 25890 21 G2P1L1 - 9.33am 400 60 460 12.8 12.2 0.6 110 120 80 70 92 16 8/10 - - Vomiting
17 Samsath begum 28563 21 G2P1L1 - 9.37am 350 60 410 12 10.8 1.2 110 110 70 80 88 15 8/10 - - -
18 Krishna veni 27090 21 G2P1L1 - 9.42am 360 80 440 10 9.4 0.6 120 110 80 80 94 14 8/10 - - -
19 Priya 29942 29 G2P1L1 - 9.50am 380 60 440 10.4 9.8 0.6 110 120 70 80 98 16 8/10 - - vomiting
20 Kalpana 30678 28 G2P1L1 - 9.38am 400 70 470 11 10.2 0.8 120 110 80 70 92 14 7/10 - - -
Fall in Hb% 
(gm/dl)
APGAR
Use  of 
additional 
oxytocins
Complicat
ion
Adverse 
Effects
Time of giving 
skin incison
Placental 
delivery to end 
of CS
End of CS to 
2 hrs 
Postpartum
Total
Before 
Delivery
24 Hrs After  
delivery
vitals
Blood Loss (ml) HB % (gm/dl) BP
S. 
No.
NAME IP No
Age 
(years)
Parity
Time of 
giving 
tranexemic 
acid
MASTER CHART WITHOUT TRANEXEMIC ACID 
 
  
 
  
21 Ushana begum 31480 26 G2P1L1 - 9.47am 370 80 450 11.2 10.4 0.8 110 120 70 80 90 16 8/10 - - nausea
22 Revathi 30947 28 G2P1L1 - 11.02am 400 60 460 11.8 10 1.8 120 110 80 70 94 14 8/10 - -- -
23 Parvathi 31340 35 G2P1L1 - 11.12am 950 100 1050 13.9 10 3.9 110 100 70 60 92 16 8/10 oxytocin PPH -
24 Pushparani 32479 29 G3P1L1A1 - 10.15am 380 80 460 10.4 9.2 1.2 120 110 80 80 98 14 8/10 - - -
25 Laila 33492 28 G2P1L1 - 10.29am 400 70 470 12 11.2 0.8 100 110 60 60 96 16 8/10 - - -
26 Saranya 35701 27 G3P2L1 - 11.05am 380 80 460 10.8 9.8 1 110 120 70 70 86 16 8/10 -- - nausea
27 Sujitha 34422 26 G2P1L1 - 12.20pm 400 80 480 12 11.2 0.8 120 110 80 70 96 15 8/10 - - -
28 Divya 36523 33 G4P1L1A2 - 10.18am 380 70 450 11 10.6 0.4 110 110 70 80 90 18 8/10 - - -
29 Sheela devi 36538 32 G2P1L1 - 9.33am 390 60 450 12.2 11..6 0.6 120 110 80 70 92 16 8/10 - - nausea
30 Kala 34711 29 G2P1L1 - 11.00am 360 70 430 10.2 9.4 0.8 120 110 80 80 88 14 8/10 - - vomiting
31 Nandhini 37099 20 G2P1L1 - 9.50am 400 50 450 10.8 10.4 0.4 1001 110 80 80 94 16 8/10 - - -
32 Jeeva rani 36604 23 G2P1L1 - 10.43am 920 90 1010 12 9.6 2.4 120 100 80 60 86 16 8/10 oxytocin PPH -
33 Saraswathi 32264 22 G2P1L1 - 10.43am 380 60 440 11.2 10.6 0.6 110 120 70 80 88 14 8/10 - - -
34 Uma maheshwari 37823 26 G3P1L1A1 - 10.33am 380 70 450 12 11.4 0.6 120 110 80 70 90 15 8/10 - - -
35 Visalatchi 38909 24 G2P1L1 - 9.47am 350 80 430 10 9.2 0.8 110 120 70 80 92 14 8/10 - - nausea
36 Nandhini 40529 24 G2P1L1 - 9.43am 400 60 460 10.4 9.8 0.6 110 120 80 80 90 16 8/10 - - -
37 Nagarani 60798 33 G3P2L1 - 9.38am 380 70 450 11.8 11 0.8 120 110 70 80 92 14 8/10 - - -
38 Lurth preetha 62435 26 G2P1L1 - 10.24am 370 70 440 12 11.2 0.8 110 120 80 70 90 18 8/10 - - -
39 Aymona beevi 63647 26 G2P1L1 - 11.02am 420 60 480 10.4 9.6 0.8 120 110 70 80 94 16 8/10 - - -
40 Dhanalakshmi 63959 28 G3P1L1A1 - 9.33am 400 80 480 9.8 9 0.8 110 110 70 70 84 14 8/10 - - -
41 Kalamani 63937 28 G4P1L1A2 - 10.20am 370 70 340 10.8 10 0.8 120 100 80 70 90 16 8/10 - - vomiting
42 Anisha 63863 20 PRIMI - 9.23am 360 80 340 11 10 1 110 120 70 80 92 14 8/10 - - -
43 Mariammal 64667 25 G3P2L1 - 9.47am 380 80 460 12 11.4 0.6 120 110 80 80 90 16 8/10 - - -
44 Sujitha 65585 27 G2P1L1 - 10.30am 400 60 460 11 10.2 0.8 110 100 70 70 92 18 8/10 - - vomiting
45 Anushya 65330 25 G2P1L1 - 11.18am 380 70 450 11.2 10.8 0.4 120 110 80 70 90 16 8/10 - - -
46 Krishna veni 68385 30 G2P1L1 - 9.38am 400 70 470 12 10.8 1.2 100 110 80 80 92 14 8/10 - - -
47 Ponnammal 69003 32 G4P1L1A2 - 9.25am 380 60 440 14 13 1 110 120 70 80 90 12 8/10 - - -
  
 
 
48 Radha mani 68388 22 G2P1L1 - 10.17am 370 70 440 13 12.2 0.8 100 110 70 70 86 14 8/10 - -       -
49 Gayathri 68890 21 G2P1L1 - 10.08am 380 60 440 10 9.4 0.6 110 100 80 80 84 16 8/10 - - vomiting
50 Manimeghalai 68033 19 PRIMI - 9.43am 400 60 460 11.8 10.4 1.4 120 110 70 70 80 14 7/10 - - -
51 Selvi 70677 26 G2P1L1 - 9.47am 380 70 450 10.2 9.8 0.4 110 120 80 80 84 14 7/10 - - -
52 Rekha 71383 23 G2P1L1 - 11.13am 400 60 460 10.8 10 0.8 120 110 70 80 86 16 8/10 - - -
53 Vanitha 70841 20 G2P1L0 - 9.47am 380 70 450 11 10.2 0.8 110 120 80 70 86 14 8/10 - - nausea
54 Usha 70857 26 G3P1L1A1 - 11.33am 380 60 440 10.2 9 1.2 120 110 80 80 86 16 8/10 - - -
55 Durga devi 72801 24 G2P1L1 - 10.25am 940 80 1020 11 8.8 2.2 110 100 70 60 98 20 8/10 oxytocin PPH -
56 Kaliya devi 74140 25 G2P1L1 - 9.43am 400 50 450 12 11.4 0.6 110 120 70 70 90 14 8/10 - - -
57 Vigneshwari 73179 19 PRIMI - 9.57am 380 60 440 12.8 11 1.8 120 110 80 70 92 16 8/10 - - -
58 Karthiga 74052 23 G2P1L1 - 11.48am 390 60 350 12.2 10.2 2 110 120 70 70 94 16 8/10 - - nausea
59 Arul mozhi 74598 31 G2P1L1 - 9.29am 940 80 1020 13 12.2 0.8 120 100 80 60 96 20 8/10 oxytocin PPH -
60 Madhavi 74605 25 G3P2L2 - 9.38am 400 60 460 12 11.2 0.8 110 120 70 80 94 16 8/10 - - -
61 Sathya 72479 24 G2P1L1 - 10.08am 380 70 450 10 9 1 120 110 80 80 96 16 8/10 - - -
62 Sapna 71755 24 G2P1L1 - 9.35am 850 110 960 11 10.2 0.8 110 100 70 80 94 14 8/10 oxytocin PPH -
63 Muneeshwari 76313 29 G2P1L1 - 9.40am 370 70 440 12 11 1 120 110 76 80 90 15 8/10 - - -
64 Benazir 76557 25 G2P1L1 - 9.30am 380 70 450 13 12.8 0.2 110 110 70 80 92 16 8/10 - - -
65 Poongodi 76556 32 G3P2L2 - 9.38am 380 80 460 12 11.2 0.81 120 100 80 80 90 14 8/10 - - vomiting
66 Anitha 53932 23 G2P1L1 - 9.43am 400 50 450 11 9.8 1.2 100 110 80 80 92 16 8/10 - - -
67 Saradha 54508 25 G3P1L1A1 - 9.45am 370 50 420 12.4 11.8 0.6 110 100 70 80 94 14 8/10 - - nausea
68 Jothi mani 53379 26 primi - 9.22am 400 60 460 12 10.6 1.4 110 120 80 80 90 12 8/10 - - -
69 Preetha 53842 30 G3P1L1A1 - 9.20am 380 60 440 13 12 1 100 110 70 80 92 14 8/10 - -
70 Malathi 52442 22 G3P1L1A1 - 9.23am 960 80 1040 11.8 10 1.8 110 100 80 70 98 16 7/10 Oxytocin PPH -
71 Mano ranjitham 47212 28 G4P1L1A2 - 9.28am 350 90 440 11.2 11 0.2 120 110 70 70 92 14 8/10 - - -
72 Jameela 47212 28 G2P1L1 - 10.27am 360 80 440 12.2 11.6 0.6 100 120 80 80 90 16 8/10 - - nausea
73 Amirthajothi 49681 23 G3P2L1 - 9.27am 370 80 450 11.4 10.8 0.6 110 120 70 70 96 14 8/10 - - -
74 Thamarai 50106 20 G2P1L1 - 9.37am 400 50 450 11.8 11 0.8 120 120 80 70 94 12 8/10 - - -
75 Bhuvaneshwari 51718 20 G2P1L1 - 10.45am 410 70 480 12.4 11.6 0.8 110 100 70 80 90 16 7/10 - - -
  
 
  
KEY TO MASTER CHART 
LSCS       Lower Segment Caesarean Section 
BL           Blood Loss 
HR          Heart Rate 
RR          Respiratory Rate 
BP           Blood Pressure 
SBP        Systolic blood Pressure 
DBP       Diastolic Blood Pressure 
G            Gravid 
P             Para 
A            Abortion 
L            Live birth 
Primi     Primi gravida 
Hb         Hemoglobin 
 
 
 
 
  
 
INFORMED CONSENT FORM 
TITLE OF THE TOPIC: 
“EVALUATION  OF EFFECTIVENESS OF  PROPHYLACTIC 
PARENTERAL TRANEXEMIC ACID IN REDUCING  BLOOD 
LOSS DURING AND AFTER ELECTIVE LOWER SEGMENT  
CESAREAN SECTION  " 
A RANDOMIZED CASE CONTROLLED PROSPECTIVE STUDY 
PURPOSE OF RESARCH 
I have been informed that this study will test the efficacy of 
tranexamic acid in reducing blood loss during and after cesarean section. 
No side effects were noted in mother as well as in neonate. 
PROCEDURE 
I understand that I will be assigned a group of patients for LSCS.I 
will be examined and a series of questions will be asked by resarcher. My 
history and physical finding will be recorded. My results will be evaluated 
in a systemic way. I will not be asked for any follow up. 
 
 
  
 
RISK AND DISCOMFORTS 
I understand that I may have some discomfort due to IV 
administration of tranexamic acid .There are no major risks involved and 
side effects are minimal. 
 BENEFITS 
I understand that my participation in the study will have direct 
benefit to me, it is mainly designed to decreases the blood loss during and 
after LSCS. 
CONFIDENTIALITY 
I understand that medical information produced by this study will become 
part of hospital record and will be subject to confidentiality record and 
privacy regulation of Coimbatore Medical College & Hospital.  
REQUEST FOR MORE INFORMATION 
I understand that I may ask more questions about the study at any 
time and understand that I will be informed of any significant new finding 
discovered during the course of this study which might influence my 
continued participation. 
  
 
If during the study or later I wish to discuss my participation or 
concerns regarding this study with a person not directly involved I am 
aware that the other staff members are available to talk with me. 
The copy of this consent form will be given to me to keep for careful 
reading. 
REFUSAL OR WITHDRAWAL OF PARTICIPATION 
I understand that my participation is voluntary and that I may refuse 
to participate or withdraw consent and discontinue participation in the 
study at  any time without prejudice to my present or future care in the 
hospital and also understand that the researcher may terminate my 
participation in the study if at any time she feels the need and explain me 
the reason to do so and help to arrange for my further appropriate treatment 
INJURY STATEMENT 
I understand that in the unlikely event or any injury due to my 
participation in the study will be reported promptly, then medical treatment 
will be available to me but no further compensation would be provided by 
the hospital. I understand that by my agreement to participate in this study 
I am not waiving any of my legal rights. 
  
 
I have explained to Mrs. __________________________________ 
the purpose of the research, the procedures required and the possible risks 
and benefits to the best of ability. 
 
Investigator:  
Date: 
 
I confirm that the researcher has explained to me the purpose of 
research the study procedures that I will undergo and the possible risks and 
discomforts as well as benefits that I may experience. Alternatives to my 
participation in the study have also been discussed. I have read and I 
understand this consent form. Therefore, I agree to give my consent to 
participate as a subject in this research project. 
 
Participant:   
 
Date: 
  
  
 
xg;g[jy; gotk; 
 
bgah;   : 
taJ   : 
ghypdk;  : 
Kfthp  : 
 
 muR nfhit kUj;Jtf; fy;Y}hpapy; kfg;ngW kw;Wk; bgz;fs; kUj;Jt 
Jiwapy;  gl;;l nkw;gog;g[ gapYk; khztp r.nfh. tpIa;_ mth;fs; 
nkw;bfhs;Sk; “mWit rpfpr;ir gpurtj;jpd; nghJk; mjd; gpd;dh] Vw;gLk; 
,uj;j ,Hg;igf; Fiwg;gjpy; Oudrpkpf; mkpyj;jpd; jpwd; - xU kjpg;gPL” 
gw;wpa Ma;tpy; bra;Kiw kw;Wk; midj;J tpsf;f';fisa[k; nfl;Lf; 
bfhz;L vdJ re;njf';fis bjspt[g;gLj;jpf; bfhz;nld; vd;gij 
bjhptpj;Jf; bfhs;fpnwd;. 
 ehd; ,e;j Ma;tpy; KG rk;kjj;JlDk;/ Ra rpe;jida[lDk; fye;J 
bfhs;s rk;kjpf;fpnwd;. 
,e;j ma;tpy; vd;idg; gw;wpa midj;J tptu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; btspaplg;gLtjpy; 
Ml;nrgid ,y;iy vd;gij bjhptpj;Jf; bfhs;fpnwd;. ve;j neuj;jpYk; ,e;j 
Ma;tpy; ,Ue;J ehd; tpyfpf; bfhs;s vdf;F chpik cz;L vd;gija[k; 
mwpntd;. 
,lk; : 
njjp :        ifbahg;gk; / nuif 
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